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The high incidence of HIV among people who inject drugs (PWID) demands 
closer examination of the drivers of transmission in this population. The burden of 
depression is high among PWID and may lead to persistent injecting behaviors, 
insufficient use of antiretroviral therapy (ART), and uncontrolled viremia. This 
dissertation study investigates the role of depression in transmission risk behaviors, 
ART initiation, and viral suppression, and models secondary transmission events 
among PWID in Vietnam, a key population in the country’s HIV epidemic.  
We analyzed data from 455 PWID living with HIV who enrolled in a randomized 
controlled trial of a prevention intervention in 2009-2013. Study visits every six months 
over two years measured depressive symptoms using the Center for Epidemiologic 
Studies Depression Scale (CES-D). Combining causal inference methods with 
mathematical modeling, we estimated the effect of depression as risk differences (RDs) 
in injection equipment sharing and condomless sex, cumulative incidence differences 
(CIDs) in ART initiation and viral suppression, and differences in total secondary 
transmissions projected to arise from participants. 
The prevalence of severe depressive symptoms (CES-D ≥23) was 44% at 
baseline and 33% on average over follow-up. Severe depressive symptoms (vs. no or 
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mild symptoms) increased injection equipment sharing (RD = 3.9 percentage points, 
95% CI: -1.7, 9.6) but decreased condomless sex (RD = -1.8, 95% CI: -6.4, 2.8) in the 
period three to six months later. Severe depressive symptoms lowered the cumulative 
incidence of ART initiation at six months (CID = -7.5, 95% CI: -17.2, 2.2) and 12 months 
(CID = -7.1, 95% CI: -17.9, 3.7), without appreciable differences in viral suppression. 
Across modeling analyses, the highest numbers of secondary transmissions were 
modeled for participants with severe depressive symptoms. However, there was 
substantial variability in model simulations due to the majority of transmissions arising 
from a small number of participants.  
Future work probing these mixed findings for the effect of depression on sharing 
injection equipment (but not condomless sex) and on ART initiation (but not viral 
suppression) will inform the design of interventions for PWID and shed light on the 
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CHAPTER I: SPECIFIC AIMS 
Despite global progress in controlling the HIV epidemic, people who inject drugs 
(PWID) remain disproportionately at risk of HIV infection (1–3). Sharing drug 
preparation and injection equipment is one of the most efficient means of HIV 
acquisition and transmission (4,5), with injection drug use accounting for nearly one-
third of HIV cases outside of sub-Saharan Africa (6,7). For PWID living with HIV, 
barriers to HIV care engagement and antiretroviral therapy (ART) use can inhibit viral 
suppression, resulting in onward HIV transmission to susceptible partners (8–10). 
Equipment sharing in the absence of viral suppression continues to sustain the HIV 
epidemic among PWID, particularly in Asia and eastern Europe (11,12). 
Reducing injection behaviors and achieving widespread ART use present 
significant challenges (13–15), and the high burden of depression among PWID may be 
at the root of those challenges. Up to 50% of PWID suffer from severe depressive 
symptoms (16–20), and although not focused on PWID, a large body of research has 
linked depression to poor HIV treatment outcomes (18,21–32). There is also some 
evidence that depression promotes behaviors associated with transmission risk to 
injecting and sexual partners, such as sharing equipment and condomless sex (33–41). 
This combination of risk behaviors and uncontrolled viremia – potentially driven by 
depression – may then facilitate forward HIV transmission to susceptible partners. 
Despite these possible links, the role of depression in HIV transmission among PWID 
 
 2 
has not been investigated, and the potential prevention impacts of depression 
interventions for PWID remain unknown. 
The role of depression in HIV transmission among PWID is critical to investigate 
in Vietnam. Vietnam has one of the highest burdens of injection drug use worldwide, 
with an estimated 335,000 active PWID (42) and a history of societal marginalization 
and stigmatization of this vulnerable group (43,44). This study focused on 455 PWID 
who enrolled in a randomized controlled trial of an HIV prevention intervention in Thai 
Nguyen, Vietnam from 2009 to 2013 (45). In the trial, depression was assessed with the 
Center for Epidemiologic Studies Depression Scale (CES-D) (46), a measure of current 
symptoms widely used among PWID (47–49) and validated in Vietnam (50,51). Our 
prior work found that nearly half of trial participants experienced severe depressive 
symptoms (20), and in this study, we investigated the role of depression in HIV 
transmission by addressing the following three aims:  
Aim 1: Estimate the association of depression with transmission risk 
behaviors. Questionnaires implemented every six months over two years assessed 
injection equipment sharing and condomless sex in the past three months. Previous 
studies of the relationship between depression and these behaviors have been unable 
to infer causality, as they have evaluated only the cross-sectional association between 
contemporaneously assessed depression and behaviors and have not accounted for 
the episodic nature of depression and confounders. We sought to overcome past 
methodological issues by using a causal approach that incorporated the episodic nature 
of depression and controlled for time-varying confounders. We hypothesized that 
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depression among PWID with HIV increased both injection equipment sharing and 
condomless sex over two years of follow-up. 
Aim 2: Estimate the association of depression with ART initiation and viral 
suppression. At each trial visit, data were collected on physician- and self-reported 
ART use, and to obtain viral load data for this study, we performed HIV RNA testing on 
stored plasma specimens. Although an inverse relationship between depression and 
HIV treatment outcomes has been established, prior work has not focused on PWID; 
studies have been conducted among clinical cohort patients who were engaged in HIV 
care. This analysis provides insights into the association between depression, ART 
initiation, and viral suppression specifically in the PWID population, with most 
participants not in care at the start of follow-up. We hypothesized that PWID with 
depression had lower cumulative incidences of ART initiation and viral suppression, 
compared to PWID without depression. 
Aim 3: Quantify the overall role of depression in HIV transmission by 
modeling secondary HIV transmission among PWID. We developed a mathematical 
model that combined behavioral and viral load data to estimate secondary HIV 
transmission events from PWID to their potentially susceptible injecting partners. While 
prior research has focused on individual components of transmission risk (e.g., 
behaviors or viral load), this model is the first to investigate the overall contribution of 
depression to HIV transmission through the combination of behavioral and biological 
pathways. We hypothesized that greater secondary transmissions during the study 




This study combined causal inference methods with mathematical modeling to 
better understand the HIV epidemic and guide control efforts among PWID with HIV in 
Vietnam. The population impact of HIV prevention efforts will be compromised if the 
underlying causes of transmission are not addressed. Depression screening and 
treatment may be critical to reducing risk behaviors, increasing viral suppression, and 






CHAPTER II: BACKGROUND 
The HIV epidemic contributes to substantial morbidity and mortality worldwide, 
resulting in 78 million infections and 35 million deaths to date (52–54). For people living 
with HIV, ART is successful in controlling viral replication, slowing progression to AIDS, 
and reducing risk of HIV transmission (55,56). However, there remain significant global 
disparities in controlling the epidemic; a particularly vulnerable group are PWID (1,3,6). 
HIV can be spread if certain bodily fluids (e.g., blood) from a person with HIV come into 
contact with a mucous membrane or damaged tissue or directly enter the bloodstream, 
making the sharing of injection drug use equipment one of the most efficient means of 
HIV transmission (4,5). Because most PWID with HIV have limited access to and 
insufficient use of harm reduction services and ART (2,9,10), injection drug use and 
viremia often persist, resulting in a high risk of HIV transmission to injecting or sexual 
partners (8–10). The combination of equipment sharing in the absence of viral 
suppression results in continued HIV incidence among PWID, particularly in southeast 
Asia, central Asia, and eastern Europe (11,12). 
In Vietnam, HIV prevalence has risen above 30% among PWID in several 
provinces (57–59). Although PWID make up nearly half of HIV cases in Vietnam, they 
account for very few patients on ART (13). PWID in Vietnam experience multi-level 
barriers to ART access and adherence; qualitative work has shown that these include 
ongoing drug use and withdrawal symptoms, lack of social support, anticipated 
stigmatization from providers, financial burden, and limited clinic access (60). There is 
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an urgent need for prevention programs to facilitate ART use for PWID living with HIV 
and reduce transmission to partners, as reflected in recent HIV prevention trials 
assessing the feasibility of future interventions for PWID in Vietnam (61). Risk reduction 
and viral suppression are both critical components of combination HIV prevention 
(15,55), but their success among PWID relies on addressing barriers unique to this 
population. 
Vietnam has one of the highest burdens of injection drug use worldwide, with an 
estimated 200,000-300,000 PWID (7,42) and a history of societal marginalization and 
stigmatization of this vulnerable group (43,44). In the early 2000s, government policies 
to address drug use in Vietnam grew repressive and punitive, instituting compulsory 
detoxification and detention facilities known as “06 centers.” From 2006 to 2010, there 
were 169,000 admissions to 06 centers, where residents encountered crude attempts at 
detoxification, “moral education”, and forced labor (62). This stigmatization of injection 
drug use hindered the efforts of policy leaders and healthcare workers in advocating for 
and implementing evidence-based harm reduction interventions (63). Beginning in 
2008, substance use treatment policy in Vietnam began to shift, as pilot programs for 
methadone maintenance demonstrated significant impacts on relapse rates (64) in 
addition to improved healthcare utilization and cost effectiveness (65). The government 
committed to expansion of the methadone maintenance program, and in 2013, formally 
recognized drug addiction as a chronic condition due to both biological and 
psychosocial causes, rather than simply a “social evil.” With this commitment to 
evidence-based addiction treatment, the government has taken steps to reduce 06 
centers; in 2015, the number of residents had fallen to 15,500 (63).  
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Despite transitioning to a more progressive approach on drug use in recent 
years, Vietnam’s history of punitive policies and severe stigmatization have deterred 
PWID from accessing health services, such as HIV testing and treatment. This group is 
difficult to reach for intervention (13), and even when PWID do enter care, simply 
offering ART is insufficient for successful HIV treatment and prevention. A substantial 
proportion continue to engage in (or relapse to) injection drug use without achieving 
viral suppression (66). Insufficient adherence to ART is common and can lead to 
treatment failure and development of drug resistance (67–69). This persistence of 
injecting behaviors, limited engagement in HIV care, and poor adherence to ART have 
significant implications for continued HIV spread among PWID, particularly due to the 
high transmission probability of parenteral exposure (4). In order for prevention efforts to 
be successful, these challenges to risk reduction and viral suppression must be 
addressed, and the mental health of PWID may be at the root of these challenges. 
The burden of depression is high among PWID and may interfere with HIV 
prevention efforts. Depression (also known as major depressive disorder or clinical 
depression) is characterized by symptoms of sadness, hopelessness, loss of interest or 
pleasure, feelings of guilt or low self-worth, sleep and appetite disruptions, fatigue, and 
poor concentration (70). In Vietnam, the translation and clinical term for depression is 
trầm cảm, and qualitative work in Vietnam has found that ART clients conceptualize 
depression primarily as a loss of social support, acute stigma and isolation, and suicidal 
thoughts (71). In Vietnam and other areas, depression has been found to be 
exceedingly common among PWID (16–20). In our prior work in Vietnam, we found that 
44% of PWID living with HIV reported severe depressive symptoms (20) as assessed 
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with the CES-D (46). The CES-D is a measure of current depressive symptoms widely 
used among PWID (47–49) and validated in Vietnam (50,51). Although not a clinical 
diagnostic, a score of 16 or greater indicates probable depressive symptoms in the 
general population, with higher cut-points used for patients with comorbid chronic 
illness, such as HIV (50); notably, our study used a conservative cut-point of 23 to 
indicate severe depressive symptoms. This estimate of 44% is considerably higher than 
pooled prevalence estimates of depression for people living with HIV that range from 
13% to 24% (72) and global estimates that 4.4% of the world’s population suffers from 
depression (73).  
The relationship between depression and injection drug use is complex. There is 
evidence that depression is a risk factor for injection drug use (74,75) and that 
depressive symptoms may be substance-induced (76) or a consequence of stigma and 
isolation experienced by PWID (77). Regardless of whether depression precedes or 
results from drug use, its presence and severity are closely linked to frequency of 
injection and risks of relapse or remission (48,74,78). This interconnected nature of 
depression and injection drug use fits into the broader psychological framework that 
depressed mood manifests as cognitive distortions, maladaptive coping, and loss of risk 
aversion (79). These symptoms of depression may then facilitate the “perfect storm” of 
behavioral and biological conditions that enable HIV transmission to occur.  
Although not focused on PWID, a large body of research shows that depression 
consistently results in worse HIV outcomes for people living with HIV and depression, 
compared to those without depression (18,21–32). Depression has been linked to lower 
initiation of and adherence to ART (21–23), poorer attendance at HIV care visits (30), 
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decreased CD4 cell count (18,23,26), higher viral load (23,24,26,28,30,31), and greater 
risk of mortality (29,32). There is also some evidence that depression promotes 
behaviors associated with transmission to injecting and sexual partners, such as 
sharing injection equipment and condomless sex (33–41). This combination of ongoing 
behaviors and uncontrolled viremia – potentially driven by depression – must be 
addressed to slow the spread of the epidemic among PWID and susceptible partners.  
While depression is recognized as a high burden among people living with HIV, 
the extent to which depression treatment could prevent future HIV spread is not well 
understood. There are numerous evidence-based pharmacologic and 
psychotherapeutic approaches for treating depressive symptoms (80), and among 
people living with both HIV and depression, depression interventions have included 
antidepressant medication, cognitive behavioral therapy, and problem solving therapy 
(79,81–87). To date, few studies have examined the effect of depression treatment on 
injecting and sexual behaviors (79,85), none among PWID with HIV. There is 
accumulating evidence that depression treatment can promote adherence to 
antiretroviral therapy and viral suppression (81–84). Improving our understanding of the 
role of depression in HIV transmission will lay the groundwork for future research on 
depression treatment among PWID and potential impacts on HIV transmission. 
Historically, mental health services in Vietnam have focused on schizophrenia and other 
conditions treated in inpatient settings, but there is growing attention and funding for 
increasing local services and the availability of treatment outside of inpatient settings 
(88,89). Depression is a prioritized condition in Vietnam (88), and improved access to 
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depression treatment has the potential to confer important benefits in terms of both 
mental health and HIV prevention.  
Significance 
Controlling the HIV epidemic among PWID may require addressing depression 
as an underlying cause of uncontrolled viremia and ongoing behaviors that result in 
transmission to injecting or sexual partners. Prior studies have found that depression is 
exceedingly common among PWID and is associated with poor HIV outcomes; 
however, the current research lacks a unified perspective that considers these individual 
associations together and assesses the overall effect of depression on onward 
transmission. Persistent injecting and sexual behaviors in conjunction with low viral 
suppression are the key drivers of forward HIV spread. Yet, no prior study has 
combined empirical data on both behaviors and viral load to investigate how depression 
may facilitate these conditions for HIV transmission to occur. If depression is fueling the 
HIV epidemic among PWID, then the recognition and treatment of depressive 
symptoms is imperative, not only for health outcomes of PWID, but for slowing the 
spread of HIV to susceptible partners.  
This study represents an important step to better understanding and controlling 
the HIV epidemic among PWID. To build on prior research, we used causal inference 
methods to estimate the associations of depression with transmission risk behaviors, 
ART initiation, and viral suppression for PWID living with HIV in Vietnam. By developing 
a mathematical model, we estimated secondary HIV transmission events from PWID to 
their potentially susceptible partners and quantified the overall role of depression in 
forward transmission. Given continued HIV incidence among PWID and the plausible 
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role of depression therein, it is critical to better understand how depression may drive 
onward transmission and the extent to which successful depression treatment could 
avert future infections. 
Innovation 
This study is an innovative approach, combining causal inference methods with 
mathematical modeling to quantify the role of depression in promoting injecting and 
sexual behaviors, hindering ART initiation and viral suppression, and ultimately 
contributing to forward HIV transmission among PWID in Vietnam, a key population in 
the country’s HIV epidemic.  
In Aim 1, we used a causal approach to overcome past methodological issues in 
estimating the effect of depressive symptoms on the injecting and sexual behaviors that 
can facilitate HIV transmission or acquisition. To our knowledge, all previous studies 
have assessed only correlations between depression and behaviors (without inferring 
causality) and have not accounted for the episodic nature of depression and 
confounders (33–41). Potentially due to these methodological issues, existing evidence 
for associations between depression and transmission risk behaviors has been 
inconsistent. In this study, we used marginal structural models, a tool for causal 
inference that controlled for time-fixed and time-varying confounders (90–92); this 
modeling approach also temporally separated depression from behaviors and 
accounted for the episodic nature of depression. With this innovative approach, we 
sought to advance our understanding of the role of depression in HIV transmission 
through its effect on behavior. 
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In Aim 2, we expanded upon pre-existing research linking depression to poor HIV 
treatment outcomes (18,21–32) by investigating these associations in the PWID 
context. A large body of literature has found lower ART initiation and viral suppression 
in clinical cohorts of HIV patients engaged in care, with little (if any) ongoing injection 
drug use. In contrast, the majority of our study population was not in care at the start of 
follow-up and all reported current injection drug use. Thus, our analysis provides 
insights into the association between depression, ART initiation, and viral suppression 
outside of well-established clinical cohorts and specifically among PWID.  
In Aim 3, the development of a mathematical model of HIV transmission among 
PWID is novel. HIV spread through sexual transmission has been the focus of previous 
modeling work, with fewer studies exploring the contribution of injection drug use to the 
epidemic (14,15,93–98) We developed a Bernoulli process mathematical model to 
estimate the expected number of secondary HIV transmission events from study 
participants (99), incorporating each participant’s specific behaviors, numbers of 
partners and acts within those partnerships, and transmission probability given viral 
load. Previously developed Bernoulli models among PWID used little empirical data and 
instead relied on simplistic and likely inappropriate assumptions, such as assuming a 
constant probability of transmission regardless of behavior type or an individual’s stage 
of infection (93). In contrast, our model used behavior and viral load data measured 
directly from the study population to account for realistic heterogeneity in HIV 
infectiousness.  
Using this model, our study is the first to quantify the role of depression in 
ongoing HIV transmission among PWID. Although a large body of research has studied 
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depression and individual components of transmission risk (e.g., behaviors or viral 
load), this model is the first to investigate the net contribution of depression to HIV 
transmission through the combination of behavioral and biological pathways. The output 
of Bernoulli models (the expected number of onward transmission events per individual) 
is a useful and meaningful quantity, with a history of informing HIV prevention efforts 
(100). Contrasting model estimates by depression enables us to quantify the potential 
excess transmission predicted for participants with depression. These estimates of 
secondary transmission also lay the groundwork for future modeling work that projects 
the potential HIV prevention benefits (i.e., numbers of infections averted) that could be 





CHAPTER III: METHODS 
 
Overview 
The overall goal of this study is to investigate the role of depression in HIV 
transmission among PWID in Vietnam. Longitudinal data from a randomized controlled 
trial of an HIV prevention intervention among PWID in Vietnam were used to estimate 
the effect of depression on transmission risk behaviors (Aim 1), ART initiation and viral 
suppression (Aim 2), and secondary HIV transmission events (Aim 3).  
Figure 3.1 depicts the conceptual model underlying all methods for this study. In 
Aims 1 and 2, we estimated the effect of depression on the key determinants of HIV 
transmission: behaviors and viral load. We hypothesized that in the context of injection 
drug use, depressive symptoms manifest as maladaptive coping and loss of risk 
aversion, resulting in a higher likelihood of sharing injection drug use equipment and 
engaging in condomless sex, while also making this group difficult to reach for 
interventions to change these behaviors. In addition, depressive symptoms were 
hypothesized to decrease health-seeking behaviors, which hindered engagement in HIV 
care and medication adherence, resulting in unsuppressed viremia. For Aim 3, we used 
data on both behaviors and viral load to estimate secondary HIV transmission events, 
hypothesizing that depression led to excess transmission through the combination of 









This dissertation study was nested within a randomized controlled trial of a multi-
level HIV stigma and risk reduction intervention that enrolled PWID living with HIV in 
Thai Nguyen, Vietnam from 2009 to 2013 (known as the “Prevention for Positives” trial; 
ClinicalTrials.gov identifier: NCT01689545). Thai Nguyen is a province in northeastern 
Vietnam with an estimated HIV prevalence of 34% among its approximately 6,000 
PWID (57–59). Out of 180 sub-districts in Thai Nguyen, participants were recruited via 
snowball sampling from the 32 sub-districts with the most PWID. Recruiters (former and 
current PWID) approached members of drug networks in private places to discuss study 
enrollment and then accompanied or referred interested participants to the study site for 
screening. At screening, participants were tested for HIV using two rapid EIA tests run 
simultaneously (Determine: Abbot Laboratories, Abbott Park, IL and Bioline: SD, 
Toronto Canada), with discordant results resolved with a third rapid assay (HIV Rapid 
Test: ACON, San Diego, CA).  
Enrolled participants met the following eligibility criteria: 1) HIV-positive 
(confirmed through study testing), 2) male (because 97% of PWID in Thai Nguyen are 
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male, and females would require a different intervention), 3) age ≥18 years, 4) reported 
having sex and injecting drugs in the prior six months, and 5) planned to live in Thai 
Nguyen for the next 24 months. 
A two-stage process was used to randomize the 32 sub-districts of participants to 
a structural-level intervention and to randomize the 455 participants across sub-districts 
to an individual-level intervention (45). This process resulted in four trial arms to which 
participants could belong: 1) control (standard of care), 2) individual (individual 
intervention only), 3) sub-district (sub-district intervention only), and 4) combined 
(individual and sub-district interventions).  
The sub-district intervention aimed to reduce community-level HIV and injection 
drug use stigma, and the individual intervention sought to support participants in coping 
with HIV and reducing transmission risk behaviors. Sub-districts randomized to the 
structural-level intervention received a community-wide program consisting of a video 
screening and series of HIV education sessions, while sub-districts assigned to 
standard of care received standard messaging through educational pamphlets and 
public loudspeakers. Participants randomized to the individual-level intervention 
received enhanced HIV post-test counseling and group support sessions; those 
assigned to standard of care were delivered HIV testing and counseling in accordance 
with current Vietnamese guidelines. At the trial start in 2009, national eligibility criteria 
for ART were CD4 cell count ≤200 cells/!l and had moved to CD4 cell count ≤350 




Out of 2,136 people approached for trial recruitment in Thai Nguyen, 1,739 were 
screened for eligibility, and among those screened, 455 participants were enrolled and 
completed the baseline visit (1,215 were not eligible, and 69 did not attend the baseline 
visit or otherwise refused to participate). Follow-up visits took place at 6, 12, 18, and 24 
months following baseline. At each visit, a structured questionnaire was administered, 
and participants were asked to provide blood specimens to assess CD4 cell count. 
Written informed consent was obtained from all eligible participants at screening and 
enrollment, and at baseline and follow-up visits, participants were reimbursed 75,000 
Vietnamese Dong ($3.50 USD) plus 5,000 Vietnamese Dong ($0.23) per kilometer 
traveled. 
Measures 
At each visit, the questionnaire was administered by a trained interviewer face-to-
face in a private room at the project facility and took approximately 1-1.5 hours to 
complete. Key variables for this dissertation study from the questionnaire were 
demographics, injection drug use and other substance use, sexual behavior, 
depression, quality of life, and ART use. In addition to the questionnaire data, this 
dissertation study used measures of CD4 cell count and viral load from blood 
specimens and physician reports of participants’ ART use. Data collection methods for 













As part of the questionnaire at each visit, the CES-D was administered to assess 
depressive symptoms over the past week. The CES-D contains 20 items comprising six 
scales, each corresponding to a major aspect of depression: depressed mood, feelings 
of guilt or worthlessness, feelings of helplessness and hopelessness, psychomotor 
retardation, loss of appetite, and sleep disturbance (46). The respondent is asked to 
rank each item according to how often they felt or behaved that way over the past week, 
with four options ranging from “Rarely or none of the time (less than 1 day)” to “Most or 
all of the time (5-7 days).” Each item receives a score of 0, 1, 2, or 3, with higher scores 
reflecting greater symptomatology, and item scores are summed to calculate the total 
score, ranging from 0 to 60. The CES-D has been widely used among PWID to assess 
depression (47–49) and has been validated in Vietnam (50,51). Although not a clinical 
diagnostic, scores of ≥16 have been found to indicate probable depressive symptoms in 
the general population (46), and higher cut-points are used for patients with comorbid 
chronic illness, such as HIV (50).  
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For the main exposure of interest across Aims 1-3, we used CES-D scores to 
categorize participants by depressive symptom severity. Consistent with past work 
(20,46,50,51), we defined severe depressive symptoms as CES-D scores ≥23, mild 
depressive symptoms as scores 16-22, and no symptoms as scores <16. 
Injecting Behavior 
In the questionnaire, participants reported injection drug use from the prior three 
months. Participants were asked about the type of drug most frequently injected, the 
number of days during the past three months they injected that drug, and if they had 
ever overdosed. Participants were also asked about injection equipment sharing with 
injecting partners over the last three months, with an injecting partner defined as 
someone in the same room as or in close proximity to the participant when they were 
both injecting drugs. Participants reported a global measure of injection equipment 
sharing across all partners from the prior three months (any/none), in addition to 
detailing types and numbers of sharing behaviors per injecting partner (for up to 10 
partners). Specifically, for each partner, participants were asked to report the frequency 
in those three months of: 1) sharing the same needle or syringe, 2) sharing drug 
solution, and 3) sharing the same ampoule of distilled water or novocaine. Participants 
were also asked if each partner had HIV, with possible responses being “Yes”, “No”, or 
“Don’t know”. 
To estimate the effect of depression on transmission risk behaviors in Aim 1, the 
global measure of injection equipment sharing (i.e., any/none in the prior three months) 
was used as one of the primary outcomes (in addition to condomless sex). This global 
measure was also included in Aim 2 as a potential confounder of the relationship 
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between depression, ART initiation, and viral suppression. To model secondary 
transmissions in Aim 3, we used the partner-specific measures of types and numbers of 
sharing acts. 
Sexual Behavior 
Participants were asked if they had sex with a male or female partner without 
using a condom in the prior three months. Similar to the global measure of injection 
equipment sharing, this measure of condomless sex (i.e., any/none in the last three 
months) was used as a primary outcome for Aim 1 and included as a potential 
confounder in Aim 2. 
ART Use 
As part of the questionnaire at each visit, participants were asked if they were 
currently taking ART, and in addition, participants were seen by the study physician who 
also ascertained current ART use. The outcome of ART initiation for the Aim 2 analysis 
was defined based on both participant- and physician-reported data. A participant was 
considered to have initiated ART in the prior six months as of the first visit at which the 
study physician reported participant ART use. If the physician’s report of ART use was 
missing (occurring for 17% of study visits overall), we used the participant’s report of 
ART use in the previous six months. In prior work in this population, we found 92% 
concordance between participant- and physician-reported ART use (103). 
Viral Load 
In the parent trial, blood specimens were collected to confirm HIV infection at 
baseline and measure CD4 cell count at all visits. Because viral load was not originally 
measured, this study performed HIV RNA testing on stored blood plasma specimens 
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using COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test platform (Roche Diagnostics 
GmbH) with a lower limit of detection of 20 copies/mL. The viral load data was 
incorporated into the transmission model in Aim 3 and was used to define the outcome 
of viral suppression for the Aim 2 analysis. Participants were considered to have 
experienced the viral suppression outcome as of the first visit with viral load <400 
copies/mL. This cut-point was chosen given prior work showing that HIV transmission is 
highly unlikely when viral load is <400 (104). 
Other Covariates 
Potential confounders included in the Aims 1-2 analyses were marital status 
(single, married or cohabitating, separated, divorced or widowed), age (in years), 
employment status (full-time, part-time, unemployed), history of overdose (yes/no), 
current alcohol use (yes/no), HIV diagnosis prior to enrollment (yes/no), CD4 cell count 
category (<200, 200-349, 350-499, ≥500 cells/µL), and intervention arm (Control, 
Individual, Subdistrict, Combined). 
Competing Events  
Study outreach workers attempted to trace participants who missed a follow-up 
visit (at 6, 12, 18, 24 months) using the contact information collected at baseline. During 
tracing procedures, outreach workers asked participant contacts if the participant had 
died or was incarcerated. These measures of death and incarceration were included as 
competing events across Aims 1-3.  
Data Analyses 
The analytic approaches for all study aims were motivated by the episodic nature 
of depression. The presence and severity of depressive symptoms changed over time in 
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the study population, as reflected by variability in CES-D score across 24 months. 
Rather than relying on a single measure of depressive symptoms, each analysis 
incorporated assessments from multiple time points to more fully capture the 
relationships between depression and the outcomes of interest. 
All analyses were conducted using R Version 3.4.3 (105). See Appendix 1 for R 
packages used in analyses.  
Aim 1 Analysis 
To estimate the effect of depression on transmission risk behaviors, we used 
marginal structural models, a method for causal inference used for time-varying 
exposures and controls for time-varying confounders (90–92,106). In the main analysis, 
we estimated the average causal effect of severe depressive symptoms (vs. mild or no 
symptoms) on the risks of any injection equipment sharing or any condomless sex 
(separately) in the period three to six months later. We evaluated each risk behavior 
outcome (reported with respect to the prior three-month period) at the next six-month 
visit in order to temporally separate it from the exposure of depressive symptoms 
(hereafter referred to as the “longitudinal effect”). In a second analysis, to facilitate 
comparison with prior research, we estimated the association between depressive 
symptoms and risk behaviors reported at the same visit, where their temporal ordering 
could not be differentiated (referred to as “cross-sectional association”). In all models, 
we controlled for time-varying confounders using the value from the visit immediately 
preceding the visit at which depressive symptoms were assessed. This modeling 




Figure 3.3. Aim 1 marginal structural modeling approach. 
 
 
We used inverse probability weighted estimation of marginal structural models 
(90,107). The weights were estimated from a propensity score model for the probability 
of severe depressive symptoms at each visit as a function of time-fixed and time-varying 
confounders, identified prior to analysis. Time-fixed confounders had a constant 
(baseline) value over all visits and included marital status, age, employment status, 
intervention arm, history of overdose, current alcohol use, HIV diagnosis prior to 
enrollment, and history of ART use. Time-varying confounders measured at one time 
point may affect subsequent depression and risk behaviors; they may also be 
influenced by depression and risk behaviors from a previous time point. Thus, time-
varying covariates may act as either confounders or mediators, depending on the time 
point assessed (90,108). For this analysis, time-varying covariates were CD4 cell count 
category, history of depressive symptoms, and history of transmission risk behaviors, 
using the value from the visit prior to the assessment of depressive symptoms.  
In the main analysis, the propensity score model was estimated using logistic 
regression to model the probability of severe (vs. mild or no) depressive symptoms. In 
secondary analyses, we used ordinal logistic regression to separately model the three 
levels of depressive symptoms (severe vs. mild vs. none). Application of the weights to 
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the study population removes the association between depressive symptoms and the 
potential confounding variables included in the propensity score model, permitting 
estimation of a causal effect under the key assumptions of consistency, conditional 
exchangeability, positivity, and no model misspecification (107,109). In the weighted 
study population, we estimated the RD for the risk behavior outcomes using generalized 
estimating equations to account for repeated observations on participants (110–112). 
For the longitudinal analysis, this weighted RD can be interpreted as the causal effect of 
depressive symptoms on the risk behavior outcome: that is, the difference in risk of the 
behavior in the period three to six months later if all participants had depressive 
symptoms compared with the risk if they all did not have depressive symptoms.  
To account for missing data due to missed study visits, we used multiple 
imputation by chained equations (MICE) for all variables included in the analysis 
(113,114), imputing and analyzing 50 datasets. We included participants who were 
incarcerated or had died during the study period in the main analysis up until the six-
month follow-up interval during which the competing event occurred, censoring them at 
that interval. In sensitivity analyses, we instead used the imputed risk behavior outcome 
for that six-month interval (and censored them at the following interval), given the 
possibility of engaging in unmeasured risk behaviors prior to incarceration or death. 
Aim 2 Analysis 
We also used inverse probability weighting to account for the time-varying nature 
of depression in our analysis of ART initiation and viral suppression. Specifically, we 
used a semi-parametric inverse probability-weighted estimator of the 6- and 12-month 
cumulative incidence of ART initiation and viral suppression (analyzed separately) 
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under three scenarios: 1) Natural course: the incidence of the outcome in the observed 
study population, 2) Never depressed: the incidence of the outcome if participants never 
had severe depressive symptoms (i.e., symptoms were mild or absent, defined as CES-
D score <23, at all study visits up to and including the visit prior to outcome 
ascertainment), and 3) Always depressed: the incidence of the outcome if participants 
always had severe depressive symptoms (CES-D ≥23 at all study visits up to and 
including the visit prior to outcome ascertainment). Death and incarceration were 
treated as competing rather than censoring events for the outcomes of interest.   
We estimated cumulative incidence under the never-depressed and always-
depressed scenarios by weighting participants who never had severe symptoms and 
who always had severe symptoms, respectively, to represent the full study population in 
terms of potential confounders of the relationship between depression, ART initiation, 
and viral suppression. These hypothesized confounders included marital status, age, 
employment status, intervention arm, CD4 cell count, self-rated general health, recent 
alcohol use, history of overdose, frequency of injection drug use, recent sharing of 
injection equipment, and recent condomless sex. The causal diagram summarizing 













Figure 3.4. Directed acyclic graph with hypothesized associations for key 




As in Aim 1, application of the weights to the study population removes the 
association between the potential confounding variables included in the model and 
depressive symptoms, permitting estimation of a causal effect between depression and 
our outcomes of interest under key assumptions of consistency, conditional 
exchangeability, positivity, and no measurement error (107,109). In the weighted study 
population, we estimated the cumulative incidence of each outcome at 6 and 12 months 
as the cumulative sum of the weights for participants experiencing the outcome, divided 
by the total sample size. To ensure that depression occurred prior to the outcome, 
outcomes lagged their assigned weight values by 6 months (i.e., baseline weight values 
were used for outcomes at 6 months; 6-month weight values were used for outcomes at 
12 months). We estimated the CID contrasting the never-depressed and always-
depressed scenarios: that is, the difference in 6- and 12-month cumulative incidence of 
the outcome (ART initiation, viral suppression) if participants always had severe 
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depressive symptoms, compared with the risk if participants never had severe 
depressive symptoms.  
We focused on cumulative incidence estimates at 6 and 12 months (rather than 
the full 24-month follow-up period) due to substantial missing data on viral load. This 
missingness was due to insufficient sample volume (<1mL) for 31% of specimens at 6 
months, 59% at 12 months, 48% at 18 months, and 55% at 24 months. To limit the 
influence of missing data, we evaluated both outcomes of interest only at the two 
earliest follow-up visits (6 and 12 months). Similar to Aim 1, we used MICE to analyze 
50 complete datasets with values imputed for missing viral load and other study 
variables with intermittent missing data not due to death or incarceration (<15% across 
all variables at all visits) (113,114). Rubin’s formula was used to pool results and 
calculate variance accounting for within- and between-imputation variability (113). 
Aim 3 Analysis 
Combining behavioral and viral load data from Aims 1 and 2, we developed a 
modified Bernoulli process mathematical model (99,115–118) to estimate the parenteral 
HIV transmissions from each study participant in two periods: the three months before 
baseline and the three months before the six-month visit. Transmission estimates were 
based on viral load measurements taken at the end of a given period, reported numbers 
of injecting partners in the period, sharing acts within those partnerships over the 
specified period, and reported partner HIV status. We limited the scope of our analysis 
to data collected at the baseline and six-month follow-up visits due to substantial 
missing data on viral load at the 12-, 18-, and 24-month visits. 
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For each named partner in a specified period, we estimated the probability that 
the participant would transmit HIV to that partner as a function of the probability that the 
partner was already HIV-infected, the number of acts between the participant and 
partner over the period, and the probability of HIV transmission in one sharing act with a 
susceptible partner. This per-act transmission probability was calculated as a function of 
the participant’s viral load. For each participant, we then summed across the partner-
specific probabilities to obtain the total number of secondary transmissions estimated 
for that participant in a given three-month period. 
Our model parameters came from both the observed data and published 
estimates from the scientific literature (Table 3.1). The number of sharing acts and the 
probability of partner HIV infection were based on questionnaire reports at baseline and 
six months. For the probability of HIV infection among partners whose HIV status was 
reported as unknown, we used an estimate of overall HIV prevalence (34%) among 
PWID in Thai Nguyen during the study period (57–59). Participant viral load was fully 
observed at trial baseline, and for missing viral load due to insufficient samples at six 
months (31% of participants), we used MICE (113,114) to impute viral suppression 
status and assign viral load. To derive the per-act transmission probability using 
participant viral load, we relied on prior transmission estimates (119–121) for the 
average viral load set-point, transmission probability per sharing act at that set-point, 
and increase in infectiousness per log10 increase in viral load above the set-point value. 
Further details about these model parameters are included in Chapter VI. 
To evaluate differences in predicted transmission events by depression, we 
stratified the population according to baseline depressive symptoms (severe, mild, or no 
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symptoms) and compared the total number of estimated transmissions by depressive 
symptom group, the probability of infection per partner, and the number of estimated 
transmissions per participant. To account for different sample sizes by depression, we 
weighted the number of total transmissions such that each group was upweighted to 
stand in for the full study population. 
 
Table 3.1. Observed and estimated Bernoulli model parameters for Aim 3. 
 
Model Parameter Estimate Source 




Assigned count  
per 90 days 
Trial data 
Literature 
(122) Never 0 
<1 time a month 1.5 
2-3 times a month 7.5 
1 time a week 12 
2-3 times a week 30 
Everyday 90 
Probability of pre-existing 
HIV infection for partner 
Participant-reported partner 
HIV status 
Assigned probability of 
HIV infection  
Trial data 
Literature 
(58,59) HIV-positive 1  
HIV-negative 0  
Unknown  0.34 
Participant’s HIV viral load Observed copies/ml with multiple imputation of viral 
suppression status where missing: 
Trial data 
Impute suppression Randomly assign viral load 1-400 
Impute no suppression Carry forward baseline value (>400) 
Viral load set-point log10 4.5 copies/ml 
Literature 
(119) 
Transmission probability at 
viral load set-point 0.008 (range 0.0063-0.024) 
Literature 
(120) 
Rate ratio per log10 







CHAPTER IV: ESTIMATING THE EFFECT OF DEPRESSION ON HIV 
TRANSMISSION RISK BEHAVIORS AMONG PEOPLE WHO INJECT DRUGS IN 
VIETNAM: A CAUSAL APPROACH 
 
Introduction 
Despite global progress in combating the HIV epidemic, PWID remain 
disproportionately at risk of HIV infection (1–3). Sharing injection equipment is an 
efficient means of HIV transmission (4,5), and high HIV incidence continues among 
PWID, particularly in southeast Asia, central Asia, and eastern Europe (11,12). Because 
PWID have limited access to and insufficient use of harm reduction services and ART 
(9,10), injection drug use and viremia often persist, resulting in a high risk of HIV 
transmission to injecting or sexual partners (8).  
Persistent risk behaviors and lack of HIV treatment engagement may be driven – 
at least in part – by a high burden of depression among PWID. Up to 50% of PWID 
suffer from severe depressive symptoms (16–20), and comorbid depression 
consistently results in poor HIV treatment outcomes (21,25–29). By lowering ART 
uptake and viral suppression, depression may also be an important driver of continued 
HIV incidence among PWID. However, while the deleterious effect of depression on HIV 
care and treatment engagement is well established, its effect on the injecting and sexual 
behaviors that can facilitate HIV transmission or acquisition is not well understood. 
Existing studies on depression and HIV transmission risk behaviors among PWID 
have suffered from several methodological limitations. To our knowledge, all previous 
studies have assessed only correlations between depression and transmission risk 
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behaviors, without inferring causality (33–41). In these studies, depression and risk 
behaviors have typically been evaluated for the same time period (e.g., self-report 
covering the last month), without the ability to infer whether depression preceded risk 
behaviors or vice versa (36–38,40,41). Potential confounders of the relationship 
between depression and risk behaviors were also measured for the same 
retrospectively assessed time period. Studies that used traditional statistical adjustment 
for these contemporaneous covariates (35,39) may have induced bias if these variables 
acted as causal mediators rather than confounders (108). In addition, although 
depression is known to be episodic (123), prior analyses have primarily relied on a 
single assessment rather than accounting for changes in both depressive symptoms 
and time-varying confounders (34,35,39,41).  
Possibly stemming from these methodological issues, existing evidence for an 
association between depression and transmission risk behaviors is inconsistent. While 
an early meta-analysis found little evidence for an association between depression and 
sexual risk behaviors (33), more recent studies have found higher sexual risk 
associated with depression (35,36,41) or a non-linear association (37) in which mild 
symptoms are most predictive of sexual risk. The few studies that have evaluated the 
association of depression with injecting risk behaviors have suggested that depressive 
symptoms were associated with greater injecting risk behaviors (36,38–40). 
Our study sought to overcome past methodological issues by using a causal 
approach to estimate the effect of depressive symptoms on transmission risk behaviors. 
We used marginal structural models, a tool for causal inference that controls for time-
fixed and time-varying confounders (90–92). Our modeling approach also temporally 
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separated depression from risk behaviors and accounted for the episodic nature of 
depression. Data for this study came from PWID living with HIV in Vietnam who 
reported behaviors associated with risk of HIV transmission to injecting partners 
(sharing injection drug use equipment) and sexual partners (condomless sex). We 
hypothesized that depression increased both injection equipment sharing and 
condomless sex over two years of follow-up. Through a methodologically rigorous 
investigation, we aimed to study depression as a potential underlying cause of HIV 
transmission and to provide clearer evidence to inform interventions against depression 
to avert future HIV infections among PWID. 
Methods 
Parent Trial Design and Population 
We used longitudinal data from a randomized controlled trial of a HIV stigma and 
risk reduction intervention among PWID living with HIV in Thai Nguyen, Vietnam from 
2009-2013 (45). The trial enrolled 455 participants who met the following eligibility 
criteria: 1) confirmed HIV diagnosis, 2) male (given that 97% of PWID in Thai Nguyen 
are male), 3) age ≥18 years, 4) had sex in the past six months, 5) injected drugs in the 
previous six months, and 6) planned to live in Thai Nguyen for the next 24 months.  
Measures 
Questionnaire and laboratory data were collected at study visits every six months 
during two years of follow-up. The questionnaire collected information on demographics, 
injection drug use and other substance use, sexual behavior, depressive symptoms, 
quality of life, and ART use. Blood specimens confirmed HIV infection at baseline and 
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measured CD4 cell count over follow-up. At baseline, participants responded to the 
questionnaire prior to receiving HIV testing results. 
The exposure of interest was depressive symptoms over the past week, as 
assessed by the 20-item CES-D, which has been validated as a reliable measure of 
depressive symptoms in Vietnam (46,50). Consistent with past work, we defined severe 
depressive symptoms as CES-D scores ≥23, mild depressive symptoms as scores 16-
22, and no symptoms as scores <16 (20,46,50,51). The transmission risk behavior 
outcomes were any sharing of injection equipment (needles, syringes, solutions, or 
distilled water) and any condomless sex, reported for the prior three months. We also 
descriptively examined the numbers of risk acts in the prior three months reported at 
each visit.  
Questionnaire and laboratory data included potential confounders of the 
depression-risk behavior relationship. Time-fixed covariates, which were assumed to be 
stable throughout the study period, were marital status, age, employment status, 
intervention arm, history of overdose, alcohol use, HIV diagnosis prior to enrollment, 
and previous ART use. Employment and alcohol use could, in theory, vary over time, 
but these variables remained fairly constant in our population, motivating our decision to 
treat them as time-fixed. Time-varying covariates measured at one time point may affect 
subsequent depression and risk behaviors; they may also be influenced by depression 
and risk behaviors from a previous time point. Thus, time-varying covariates may act as 
either confounders or mediators, depending on the time point assessed (90,108). For 
this analysis, time-varying covariates were CD4 cell count category (<200, 200-499, 
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≥500 cells/μL), history of depressive symptoms, and history of transmission risk 
behaviors. 
Statistical Analysis 
In the main analysis, we used marginal structural models to estimate the average 
causal effect of severe depressive symptoms on the risks of any injection equipment 
sharing or any condomless sex (separately) in the period three to six months later, 
controlling for time-fixed and time-varying confounders. We evaluated each risk 
behavior outcome (reported with respect to the prior three-month period) at the next six-
month visit in order to temporally separate it from the exposure of depressive symptoms 
(hereafter referred to as the “longitudinal effect”). In a second analysis, to facilitate 
comparison with prior research, we used marginal structural models to estimate the 
association between depressive symptoms and risk behaviors reported at the same 
visit, where temporal ordering could not be differentiated (“cross-sectional association”). 
We used inverse probability weighted estimation of marginal structural models 
(90,107). Weights were estimated from a propensity score model for the probability of 
severe depressive symptoms as a function of time-fixed and time-varying confounders. 
Time-fixed confounders had a constant (baseline) value over all visits; time-varying 
confounders used the value from the visit immediately preceding the visit at which 
depressive symptoms were assessed. In the main analysis, the propensity score model 
was estimated using logistic regression to model the probability of severe (vs. mild or 
no) depressive symptoms. In secondary analyses, we used ordinal logistic regression to 
separately model the three levels of depressive symptoms (severe vs. mild vs. none). 
Propensity score model diagnostics assessed positivity for all confounder-defined 
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subsets of the study population. The denominator of the weights was the predicted 
probability of depressive symptoms from the propensity score model, and weights were 
stabilized using the marginal probability of depressive symptoms in the numerator.  
Application of the weights to the study population removes the association 
between depressive symptoms and potential confounding variables included in the 
propensity score model, permitting estimation of a causal effect under key assumptions 
(107,109) (see Discussion). In the weighted study population, we estimated RD for the 
risk behavior outcomes using generalized estimating equations to account for repeated 
observations on participants (110–112). For the longitudinal analysis, this weighted RD 
can be interpreted as the causal effect of depressive symptoms on the risk behavior 
outcome: that is, the difference in risk of the behavior in the period three to six months 
later if all participants had depressive symptoms compared with the risk if they all did 
not have depressive symptoms.  
To account for missing data due to missed study visits, we used MICE (113,114), 
imputing and analyzing 50 datasets. We included participants who were incarcerated or 
died during the study period in the main analysis up until the six-month follow-up interval 
during which incarceration or death occurred, censoring them at that interval. In 
sensitivity analyses, we instead used the imputed risk behavior outcome for that six-
month interval (and censored them at the following interval), given the possibility of 
engaging in unmeasured risk behaviors prior to incarceration or death. For all estimates, 
our interpretation focuses on the point estimate and confidence interval, rather than 





This study was approved by the ethical review committees at the Thai Nguyen Center 
for Preventive Medicine, the Johns Hopkins Bloomberg School of Public Health, and the 
University of North Carolina at Chapel Hill Gillings School of Global Public Health. 
Written informed consent was obtained from all participants. 
Results 
Based on inclusion criteria, all 455 participants were male, HIV-positive, and 
reported being sexually active and using injection drugs at baseline. The median age of 
participants was 35 years (interquartile range [IQR]: 30, 39), and half were married or 
cohabitating (47%) (Table 4.1). One-third had a high school education (34%), and the 
majority were employed full-time (69%). Most participants were newly diagnosed with 
HIV at baseline (74%), while 15% had been previously diagnosed but were not taking 
ART, and 11% were previously diagnosed with current ART use. The median CD4 cell 
count was 241 cells/µL (IQR: 126, 370). General health was rated as poor by 30%. 
Nearly half reported injecting heroin daily (45%), 18% had a history of overdose, and 
67% reported current alcohol use. Participants completed between zero and four follow-
up study visits (median=4, IQR: 2, 4) at six-month intervals over 24 months, with 87% 
completing at least one follow-up visit. 
At baseline, 44% of participants reported severe depressive symptoms (CES-
D≥23), 25% had mild symptoms (16≤CES-D≤22), and 30% had no symptoms (CES-
D<16). One quarter of participants reported sex without a condom in the prior three 
months (24%), with a median of 10 condomless sex acts reported for those three 
months (IQR: 5, 20). Most participants reported sharing injection drug use equipment 
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with injecting partners over the past three months (73%); these participants reported a 
median of 21 sharing acts during those three months (IQR: 7, 52).  
After the baseline visit – when the majority of participants were diagnosed with 
HIV and received risk reduction counseling – sharing injection equipment and 
condomless sex decreased across trial arms (previously reported in (45)). However, 
among participants attending ≥1 follow-up visits (n=397), 21% reported sharing injection 
equipment at ≥1 visits, and 7% reported condomless sex at ≥1 visits. The severity of 
depressive symptoms varied over time; among participants attending ≥1 follow-up visit, 
59% experienced severe depressive symptoms at ≥1 visits (Figure 4.1). The percentage 
of participants experiencing competing events increased over time, with 8% 
incarcerated and 23% deceased at 24 months.  
In our main analysis, we estimated that severe depressive symptoms (compared 
to no or mild symptoms) increased the risk of sharing injection equipment by 3.9 
percentage points (95% CI: -1.7, 9.6) and decreased the risk of condomless sex by 1.8 
percentage points (95% CI: -6.4, 2.8) in the period three to six months later (Table 4.2, 
Figure 4.2). In the cross-sectional analyses, the association between severe depressive 
symptoms and contemporaneous injection equipment sharing (RD = 6.2, 95% CI: 1.4, 
11.0) was stronger than the estimated longitudinal effect, while the association with 
condomless sex was attenuated (RD = -0.7%, 95% CI: -4.5%, 3.0%). 
In secondary analyses using three levels of depressive symptoms, there were 
small decreases in the risk of condomless sex as depressive symptoms increased, 
although all confidence intervals overlapped substantially (Table 4.2, Figure 4.3). For 
injection equipment sharing, patterns of risk corresponding to the three levels of 
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depressive symptoms differed for the longitudinal effect versus the cross-sectional 
association. In longitudinal analyses, we observed a U-shaped relationship in which the 
risk of injection equipment sharing in the period three to six months later was 12.8% 
(95% CI: 8.1%, 17.6%) among those with no depressive symptoms, 9.2% (95% CI: 
5.3%, 13.2%) among those with mild symptoms, and 13.8% (95% CI: 9.1%, 18.5%) 
among those with severe symptoms. In contrast, in the cross-sectional analysis, we 
observed a monotonic increasing relationship in which those with no depressive 
symptoms had the lowest risk of 8.5% (95% CI: 5.3%, 11.8%) while those with mild 
symptoms had a risk of 15.5% (95% CI: 11.1%, 20.0%) and those with severe 
symptoms had a risk of 17.4% (95% CI: 13.1%, 21.8%). 
We did not find appreciable differences in sensitivity analyses that varied 
censoring time for participants who were incarcerated or deceased (Figure 4.4). 
Discussion 
Using two years of longitudinal data and methods for causal inference, we found 
that severe depressive symptoms increased the risk of sharing injection equipment but 
not the risk of condomless sex among PWID. To overcome past methodological issues, 
we used marginal structural models to capture the episodic nature of depression, 
enforce temporal ordering of depression and risk behaviors, and control time-varying 
confounding in the analysis. By focusing on PWID living with HIV in Vietnam, a 
population at high risk of ongoing HIV transmission, we aimed to better understand 
depression as an underlying cause of risk behavior and potential onward transmission.  
In our main analysis of injection equipment sharing in the period three to six 
months after assessment of depression, we found a RD of 3.9 (95% CI: -1.7, 9.6), 
 
 39 
comparing participants with severe depressive symptoms to those with mild or no 
depressive symptoms. This longitudinal effect was only slightly weaker than the 
corresponding cross-sectional association (RD = 6.2, 95% CI: 1.4, 11.0) found in the 
analysis that did not enforce temporality. Our estimate for this effect shows that a risk 
difference ranging from a 1.7 percentage point decrease, a small negative association, 
to a 9.6 percentage point increase, a substantial positive association, is compatible with 
the data. Given that the overall risk of injection equipment sharing was 10% across 
follow-up visits, the point estimate of a 3.9 percentage point increase is substantively 
meaningful.  
Previous research has suggested a possible non-linear relationship between the 
severity of depressive symptoms and occurrence of transmission risk behaviors. This 
literature has focused on sexual risk behavior, finding that mild depressive symptoms 
are associated with higher sexual risk behavior but this risk decreases with severe 
depressive symptoms (37). Our secondary analysis for the risk of condomless sex 
evaluated three levels of depressive symptoms, but findings were similar to our main 
analysis, suggesting slight decreases in condomless sex with increasing severity of 
depressive symptoms. Participants with depressive symptoms – regardless of severity – 
may be experiencing fatigue, social isolation, and loss of interest in sex, thereby 
reducing the risk of engaging in this behavior (125). 
In contrast to condomless sex, we observed possible non-linearities in the 
secondary analysis for the risk of sharing injection equipment, which have not been 
observed previously. Prior studies have found an increasing risk of injecting risk 
behavior with increasing depressive symptom severity (39) or have not differentiated 
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between mild and severe symptoms (36,38,40). We found that participants with no 
depressive symptoms had the lowest cross-sectional risk of sharing injection equipment 
(suggesting a monotonic increase in risk with increasing symptom severity), while 
participants with mild depressive symptoms had the lowest risk of sharing injection 
equipment three to six months later (suggesting a U-shaped relationship, where risk 
increased with no symptoms or severe symptoms). Interestingly, this U-shaped 
relationship for longitudinal injecting risk is the inverse of previous findings on sexual 
risk (where those with mild depressive symptoms had the highest risk) (37). This may 
be due to mild depressive symptoms manifesting differently for injecting behavior 
compared to sexual behavior. Depressive symptoms could lead to cognitive distortions, 
maladaptive coping, and loss of risk aversion (126–128), and such symptoms may need 
to become severe in order to be expressed behaviorally as increased frequency of 
injection drug use (to treat severe symptoms) and consequently, greater sharing of 
equipment.  
Although the relationship between depression and risk behaviors has been 
studied previously, the unique contribution of this study is its methodological rigor in 
inferring causality rather than correlation. Our modeling approach controlled time-
varying confounding and incorporated the episodic nature of depressive symptoms by 
using longitudinal data from five study visits over two years. Estimation of the 
longitudinal effect and the cross-sectional association differed only in the timing of 
depressive symptoms and risk behaviors. Given that the longitudinal effect enforced 
temporal ordering of depressive symptoms prior to risk behaviors, we believe that it 
more closely reflects the causal effect. However, it is important to consider the trade-off 
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between temporal ordering and etiologic relevance in the context of data limitations 
particular to this study. Separating the measurement of depressive symptoms and risk 
behaviors by six months (with a three-month “blackout period” in between) was 
necessitated by the parent trial’s data structure. A shorter time interval with more 
complete data coverage may allow better capture of the effect of episodic depressive 
symptoms on subsequent risk behavior. In addition, this incomplete interval coverage 
could have attenuated effect estimates relative to what they might have been if the 
entire interval were included (i.e., if depressive symptoms were more likely to influence 
risk behaviors in the first three months of the follow-up interval).  
Inferring causality relies on several key assumptions, which must be evaluated 
carefully in light of the limitations of this study (107,109). The assumption of no 
unmeasured confounding (i.e., that participants with and without depression are 
exchangeable) is critical to using observational studies for causal inference. Although 
we controlled for a variety of confounders, it is possible that unmeasured confounding 
biased estimates of the effect of depression on risk behaviors. We also assumed 
positivity (i.e., participants with and without depressive symptoms were in all 
confounder-defined subsets of the population) and that models were correctly specified 
without measurement error for covariates. Importantly, the CES-D is not diagnostic of 
clinical depression, and there may be measurement error if CES-D score categories do 
not reflect clinically relevant depressive symptoms. However, we used a conservative 
cut-point for severe depressive symptoms with high reliability and validity (46,50). There 
may also have been under-ascertainment of risk behaviors due to social desirability and 
recall bias. However, participants reported high levels of drug use and had been 
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recruited by former drug users (aware of their injection drug use), indicating a 
willingness to disclose sensitive behaviors. Finally, the assumption of consistency holds 
that any variability in treatment (i.e., multiple versions of treatment) is irrelevant to the 
effect of treatment on the outcome. Here, we did not model a specific treatment or 
intervention on depression. Therefore, our results should only be interpreted as the 
hypothetical effect of eliminating severe depressive symptoms without specifying the 
treatment or intervention used for elimination. 
Our conclusions are specific to this sample and may not be representative of all 
PWID living with HIV. Participants were not randomly sampled and may differ from other 
PWID with HIV in Vietnam. While men who inject drugs drive the HIV epidemic in 
Vietnam, our findings may not be applicable to other groups, such as women or PWID 
in other regions. However, our findings may be broadly generalizable to other Asian and 
European countries where the HIV epidemic is concentrated among similar groups. 
There is also increasing relevance to understanding drivers of transmission risk 
behaviors among PWID in the United States, as the current opioid epidemic has begun 
to result in explosive HIV outbreaks (129–131). Importantly, the risk behavior outcome 
in our study does not allow direct prediction of forward HIV transmission risk, as we did 
not take into account viral suppression status, the frequency of risk acts, or partner 
susceptibility to HIV. These determinants of transmission will be incorporated into a 
future mathematical modeling analysis that will explicitly estimate forward transmission 
events from this study population. 
We found through rigorous causal analysis that severe depressive symptoms 
may perpetuate the risk of sharing injection equipment among PWID living with HIV in 
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Vietnam. During the study period (2009-2013), there was very limited access to mental 
health services for people living with depression in Vietnam (88). However, in recent 
years, mental health services have become a national health priority, and there is 
growing attention and funding for increasing local services and availability of depression 
treatment (88,132). Screening and treating depressive symptoms among PWID 
presents an opportunity not only to improve mental health and drug abuse outcomes but 




Table 4.1. Characteristics of HIV-positive male PWID in Thai Nguyen, Vietnam at 
baseline and follow-up visits at 6, 12, 18, and 24 months.  
 
Characteristic at baseline (n = 455 participants) Median (IQR) or N (%)† 
Age in years (range 19-60) 35 (30, 39) 
Married or cohabitating 215 (47) 
High school education or greater 153 (34) 
Full-time employment  315 (69) 
Newly diagnosed with HIV 336 (74) 
Prior HIV diagnosis, no ART use 68 (15) 
Prior HIV diagnosis, current ART use 51 (11) 
CD4 cell count (cells/µl) 241 (126, 370) 
Self-rated health as poor 136 (30) 
Daily injection drug use  207 (45) 
History of overdose 84 (18) 
Current alcohol use 307 (67) 
Severe depressive symptoms (CES-D≥23) 201 (44) 
Any sharing of injection equipment in prior 3 months 332 (73) 
Number of sharing acts in prior 3 months (if reported any) 21 (7, 52) 
Any condomless sex in prior 3 months 108 (24) 
Number of condomless acts in prior 3 months (if reported any) 10 (5, 20) 
Characteristic over follow-up (n = 397 attended ≥1 visit) Median (IQR) or N (%)‡ 
CD4 cell count (cells/µl) 251 (148, 376) 
Any severe depressive symptoms (CES-D≥23) 235 (59) 
Any sharing of injection equipment in prior 3 months 82 (21) 
Any condomless sex in prior 3 months 29 (7) 
 
† Median and N (%) at baseline visit for all n=455 participants. 




Table 4.2. Weighted risk differences for risk behavior outcomes by depressive symptoms. 
 









RD (95% CI) 
Severe vs. Not severe Longitudinal 3.9 (-1.7, 9.6)  Severe vs. Mild Longitudinal 4.6 (-1.5, 10.7) 
 Severe vs. None Longitudinal 1.0 (-6.0, 8.0) 
Severe vs. Not severe Cross-sectional 6.2 (1.4, 11.0)  Severe vs. Mild Cross-sectional 1.9 (-4.4, 8.2) 
 Severe vs. None Cross-sectional 8.9 (3.6, 14.3) 









RD (95% CI) 
Severe vs. Not severe Longitudinal -1.8 (-6.4, 2.8)  Severe vs. Mild Longitudinal -1.0 (-6.3, 4.2) 
 Severe vs. None Longitudinal -2.6 (-8.7, 3.5) 
Severe vs. Not severe Cross-sectional -0.7 (-4.5, 3.0)  Severe vs. Mild Cross-sectional -0.0 (-4.5, 4.4) 






Figure 4.1. Distribution of depressive symptoms and competing events over 24 
months. Stacked rectangles at each time point correspond to mutually exclusive states, 
and shaded paths indicate transitions between states in each intervening 6-month 
period. The six states are severe symptoms (CES-D≥23), mild symptoms 







Figure 4.2. Weighted risks of any injection equipment sharing and any 
condomless sex by depressive symptoms. Severe depressive symptoms were 
defined as CES-D≥23; no severe symptoms were CES-D<23. We evaluated the risk 
behavior outcome at the next 6-month visit (longitudinal) to estimate the causal effect, 







Figure 4.3. Weighted risks of any injection equipment sharing and any 
condomless sex exploring three levels of depressive symptoms. The three levels 
of symptoms were severe (CES-D≥23), mild (16≤CESD≤22), and none (CES-D<16). 
For each comparison, we evaluated the risk behavior outcome at the next 6-month visit 








Figure 4.4. Weighted risk differences for injection equipment sharing and 
condomless sex by severe depressive symptoms, based on treatment of 
competing events. For participants experiencing a competing event (death or 
incarceration) during the study period, the main analysis included them up until the six-
month follow-up interval during which the competing event occurred, censoring them at 
that time. The secondary analysis instead used the imputed risk behavior outcome for 
that six-month interval (during which time the competing event occurred) and censored 








CHAPTER V: DEPRESSION, ANTIRETROVIRAL THERAPY INITIATION, AND HIV 
VIRAL SUPPRESSION AMONG PEOPLE WHO INJECT DRUGS IN VIETNAM 
 
Introduction 
Injection drug use is a key driver of the HIV epidemic, particularly in Asia and 
eastern Europe (11,12). Sharing drug preparation and injection equipment is one of the 
most efficient means of HIV acquisition and transmission (4,5). ART for people living 
with HIV can improve clinical outcomes and reduce onward transmission risk through 
viral suppression and a corresponding reduction in infectiousness (55). However, 
despite successful scale-up of HIV treatment services for PWID in some high-resource 
settings (133), ART use is insufficient for most PWID globally (9,10,134). In Vietnam, a 
setting where the HIV epidemic is concentrated among PWID (135,136), expanded ART 
use specifically among PWID could substantially reduce new infections (137); however, 
treatment is typically initiated at a late stage of infection in this population (101), 
hindering the impact of “treatment as prevention” on HIV transmission.  
Optimizing HIV treatment as prevention among PWID may require addressing 
depression as an underlying cause of low treatment engagement. Up to 50% of PWID 
suffer from severe depressive symptoms (16–20), and though not focused on PWID, a 
large body of research has linked depression to poor HIV treatment outcomes (21,25–
32). In recent work in Vietnam, we observed a high burden of depression among PWID 
living with HIV (20) and found that depression increased the risk of sharing injection 
drug use equipment (see Chapter IV). If depression concomitantly inhibits ART initiation 
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and/or viral suppression, then the corresponding increase in biological transmission risk 
resulting from depression could be amplified by these co-occurring injection risk 
behaviors.  
In this study, we sought to understand the role of depression in ART initiation and 
viral suppression among male PWID in Vietnam. We hypothesized that severe 
depressive symptoms would decrease the incidence of both ART initiation and viral 
suppression over 6 and 12 months among PWID living with HIV. Given the 
disproportionate impact of both HIV and depression among PWID, it is critical to better 
understand depression as a potential underlying cause of poor clinical outcomes and 
increased transmission risk in this population. 
Methods 
Parent Trial Design and Population 
This study was nested within a randomized controlled trial of a multi-level HIV 
stigma and risk reduction intervention that enrolled PWID living with HIV in Thai 
Nguyen, Vietnam from 2009 to 2013 (45). Thai Nguyen is a province in northeastern 
Vietnam with an estimated HIV prevalence of 34% among its approximately 6,000 
PWID (57–59). Participants were recruited via snowball sampling from the 32 sub-
districts of Thai Nguyen with the most PWID. The trial enrolled 455 participants who met 
the following eligibility criteria: 1) HIV-positive (confirmed through study testing), 2) male 
(because 97% of PWID in Thai Nguyen are male, and females would require a different 
intervention), 3) age ≥18 years, 4) reported having sex and injecting drugs in the prior 
six months, and 5) planned to live in Thai Nguyen for the next 24 months. As part of HIV 
testing and counseling at trial baseline, participants were referred to ART clinics. In 
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2009, national eligibility criteria for ART were CD4 cell count ≤200 cells/!l and had 
moved to CD4 cell count ≤350 cells/!l by 2013 (101,102). 
In a two-stage process, the 32 sub-districts where participants lived were 
randomized to a structural intervention, and the 455 enrolled participants across sub-
districts were randomized to an individual-level intervention (45). This process resulted 
in four trial arms to which participants could belong: 1) control (standard of care), 2) 
individual (individual-level intervention only), 3) sub-district (sub-district-level structural 
intervention only), and 4) combined (structural and individual interventions). The 
structural intervention aimed to reduce community-level HIV and injection drug use 
stigma, and the individual intervention provided support to participants in coping with 
HIV and reducing transmission risk behaviors. As previously reported (45), no 
differences in transmission risk behaviors were observed across trial arms.  
Measures 
Questionnaire and laboratory data were collected at study visits every six months 
during the two-year trial (baseline, 6, 12, 18, 24 months). The questionnaire was 
administered in a face-to-face interview and collected information on demographics, 
general health, injection drug use and other substance use, depressive symptoms, HIV 
transmission risk behaviors, history of HIV testing, and ART use. Blood specimens were 
collected to confirm HIV infection at baseline and to measure CD4 cell count at all visits. 
Participants responded to the baseline questionnaire prior to receiving HIV testing 
results. As part of the questionnaire at each visit, participants were asked if they were 
currently taking ART, and in addition, participants were seen by the study physician who 
also ascertained current ART use. 
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The exposure of interest was severe depressive symptoms over the past week, 
as assessed with the 20-item CES-D, which has been validated as a reliable measure 
of depressive symptoms in Vietnam (46,50). Consistent with past work including studies 
in Vietnam (20,46,50,51), we defined severe depressive symptoms as CES-D scores 
≥23 and no or mild symptoms as scores <23.  
We specified two outcomes of interest: ART initiation and viral suppression. A 
participant was considered to have initiated ART in the prior six months as of the first 
visit at which the study physician reported participant ART use. If the physician’s report 
of ART use was missing (occurring for 17% of all study visits), we used the participant’s 
self-report of ART use in the previous six months. In prior work in this population, we 
found 92% concordance between self- and physician-reported ART use (103). Because 
viral load was not measured in the parent trial, for the viral suppression analyses we 
performed HIV RNA testing on stored blood plasma specimens using COBAS® 
AmpliPrep/COBAS® TaqMan® HIV-1 Test platform (Roche Diagnostics GmbH) with a 
lower limit of detection of 20 copies/mL. Participants were considered to have 
experienced the viral suppression outcome as of the first visit with viral load <400 
copies/mL. Missing viral load data resulted from insufficient sample volume (<1mL) for 
some of the stored specimens at follow-up visits: 31% at 6 months, 59% at 12 months, 
48% at 18 months, and 55% at 24 months. To limit the influence of missing data in this 
analysis, we evaluated both outcomes of interest only at the two earliest follow-up visits 
(6 and 12 months).  
We identified potential confounders a priori as questionnaire or laboratory 
variables that could plausibly affect depression, ART initiation, and viral suppression. 
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These hypothesized confounders included marital status, age, employment status, 
intervention arm, CD4 cell count, self-rated general health, recent alcohol use, history of 
overdose, frequency of injection drug use, recent sharing of injection equipment, and 
recent condomless sex. To prevent inclusion of variables mediating the relationship 
between depression and a given outcome, all potential confounder values corresponded 
to the time period prior to exposure assessment (90,108).  
Study outreach workers attempted to trace participants who missed a visit using 
the contact information collected at baseline. During tracing procedures, outreach 
workers asked participant contacts if the participant had died or was incarcerated. We 
therefore considered death and incarceration to have been ascertained at all visits, 
allowing us to treat them as competing events for the outcomes of interest.  
Statistical Analysis 
We used a semi-parametric inverse probability-weighted estimator of the 
cumulative incidence of ART initiation and viral suppression (analyzed separately), 
accounting for the time-varying nature of depression and confounders and the 
occurrence of the competing events of death and incarceration (138,139). Participants 
who did not experience an event were administratively censored at the end of follow-up; 
no other censoring occurred. To estimate the effect of depression on the 6- and 12-
month cumulative incidence of ART initiation and viral suppression, we first estimated 
the cumulative incidence of each outcome at each time point in three scenarios: 1) 
Natural course: the incidence of the outcome in the observed study population, 2) Never 
depressed: the incidence of the outcome if participants never had severe depressive 
symptoms (i.e., symptoms were mild or absent, defined as CES-D score <23, at all 
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study visits up to and including the visit prior to outcome ascertainment), and 3) Always 
depressed: the incidence of the outcome if participants always had severe depressive 
symptoms (CES-D ≥23 at all study visits up to and including the visit prior to outcome 
ascertainment). Given that depressive symptoms vary over time, these two extreme 
conditions were intended to capture the largest possible difference: the risk of the 
outcome if participants always had severe symptoms vs. the risk of the outcome if 
participants never had severe symptoms. 
In the natural course (scenario 1), the cumulative incidence of each outcome " 
(ART initiation, viral suppression) was estimated as the number of participants who 
experienced the outcome of interest ($ = 1), rather than a competing event ($ = 2), by 
the 6- and 12-month follow-up visits () = 6, ) = 12 months), divided by the total sample 
size ,:  
-.(" ≤ 	), $ = 1) 	= 	 12 ∑ 4("5 ≤ ), 	$5 = 1)
2
561    (1) 
 
In the never-depressed scenario (scenario 2), we estimated the cumulative 
incidence of the outcome using data only from participants who were never depressed 
(7 = 1) and applied inverse probability weights 18.(9	6	1|;<) such that they represented the 
full study population based on hypothesized confounders =:   




561      (2) 
In the always-depressed scenario (scenario 3), we estimated the cumulative 
incidence of the outcome using data only from participants who were always depressed 
(Δ = 1) and applied inverse probability weights 18.(E	6	1)|;< such that they represented the 
full study population based on hypothesized confounders =:   
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561     (3) 
For the never-depressed scenario, the weights were estimated from a logistic 
regression model for the probability of no severe depressive symptoms, conditional on 
having no severe symptoms at prior visits (i.e., the model was estimated using the full 
population at baseline, and over follow-up, participants were censored from the model 
after the visit at which severe symptoms were ascertained). For the always-depressed 
scenario, the weights were estimated from a logistic regression model for the probability 
of severe depressive symptoms, conditional on having severe symptoms at prior visits 
(similarly, the model was estimated using the full population at baseline, and over 
follow-up, participants were censored from the model after the visit at which they no 
longer had severe symptoms). Both probabilities were modeled as a function of follow-
up time (in months), intervention arm (control, individual, sub-district, combined), time-
varying CD4 cell count category (<200, 200-349, 350-499, ≥500 cells/µL), and baseline 
values of marital status (single, married or cohabitating, separated, divorced or 
widowed), age (in years), employment status (full-time, part-time, unemployed), self-
rated general health (good, fair, poor), alcohol use (any/none), history of overdose 
(any/none), frequency of injection drug use (number of days injected in last 90 days), 
sharing of injection equipment (any/none in last 90 days), and condomless sex 
(any/none in last 90 days). Although several of the variables we treated as time-fixed 
(e.g., employment status, alcohol use) could, in theory, vary over time, they remained 
fairly constant in our population, motivating our decision to include only baseline values.  
Each participant’s weight at a given time point was calculated as the reciprocal of 
the cumulative product of the model-predicted probabilities for their observed 
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depression status (i.e., never-depressed or always-depressed). We evaluated the 
distribution of probabilities to assess positivity for all confounder-defined subsets of the 
study population and ensure balance of covariates in the weighted sample. Across all 
analyses, there were no extreme weight values (range between 1 and 20). 
Application of the weights to the study population removes the association 
between the potential confounding variables included in the model and depressive 
symptoms, permitting estimation of a causal effect between depression and our 
outcomes of interest under key assumptions of consistency, conditional exchangeability, 
positivity, and no measurement error (107,109) (see Discussion). In the weighted study 
population, we estimated the cumulative incidence of each outcome at 6 and 12 months 
as the cumulative sum of the weights for participants experiencing the outcome, divided 
by the total sample size. To ensure that depression occurred prior to the outcome, 
outcomes lagged their assigned weight values by 6 months (i.e., baseline weight values 
were used for outcomes at 6 months; 6-month weight values were used for outcomes at 
12 months). We estimated the CID contrasting the never-depressed and always-
depressed scenarios: that is, the difference in 6- and 12-month cumulative incidence of 
the outcome (ART initiation, viral suppression) if participants always had severe 
depressive symptoms, compared with the risk if participants never had severe 
depressive symptoms. For cumulative incidence and CID estimates, we used a 
conservative influence function-based estimator of the variance. This estimator was 
implemented by taking the variance of the differences between the cumulative incidence 
estimate and each observation’s weighted contribution.  
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In our main analyses, the cumulative incidence of each outcome was estimated 
for participants who had not experienced that outcome at baseline, resulting in slightly 
different analytic samples for the two outcomes (e.g., participants who reported ART at 
baseline, but were not virally suppressed, were included in the viral suppression 
analysis, but not in the ART initiation analysis). In a second set of analyses, we 
restricted analysis of both outcomes to the same sample (participants with neither ART 
use nor viral suppression at baseline) to facilitate more direct comparison of estimates 
across outcomes.  
There was substantial missing data due to insufficient sample volume for 
measuring viral load (31% at 6 months, 59% at 12 months) in addition to intermittent 
missing data on other study variables not due to death or incarceration (<15% across all 
variables at all visits). To address missing data, we used MICE (113,114), analyzing 50 
complete datasets with values imputed for depression, ART initiation, viral suppression, 
and all hypothesized confounders. We used Rubin’s formula to pool results from the 50 
imputed datasets and calculate variance accounting for within- and between-imputation 
variability (113). 
For all estimates, we focused interpretation on the point estimate and confidence 
interval, rather than statistical significance (124). Analyses were conducted using R 
Version 3.4.3 (105).  
Ethics 
The parent trial and this analysis were approved by the ethical review 
committees at the Thai Nguyen Center for Preventive Medicine, the Johns Hopkins 
Bloomberg School of Public Health, and the University of North Carolina at Chapel Hill 
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Gillings School of Global Public Health. Written informed consent was obtained from all 
participants. 
Results 
Among the 455 participants at baseline, the median age was 35 years (IQR: 30, 
39), nearly half (47%) were married or cohabitating, and most (69%) were employed 
full-time. Most participants (73%) reported sharing injection drug use equipment with 
injecting partners over the past three months, and one-quarter (24%) reported sex 
without a condom in the prior three months. Prior to HIV testing at baseline, 74% of 
participants reported no previous HIV diagnosis. Table 5.1 shows additional 
characteristics of the study population.  
The percentage of participants with severe depressive symptoms (CES-D ≥23) 
was 44% at baseline, decreasing to 37% at 6 months and 25% at 12 months (Table 
5.1). This decreasing prevalence of depression over time was likely due in part to 
disproportionately higher risks of competing events over follow-up among participants 
who had severe depressive symptoms at baseline (Table 5.2, Figure 5.2). At baseline, 
only 13% of participants reported current ART use; this percentage increased to 33% 
and 36%, at 6 and 12 months, respectively. There was a slight increase in CD4 cell 
count from baseline (median 241 cells/µL) to 6 months (median 251 cells/µL) and 12 
months (260 cells/µL). The median HIV viral load was 4.3 log10 copies/mL at baseline, 
decreasing to 3.6 log10 copies/mL at 6 months, and then increasing to 3.9 log10 
copies/mL at 12 months. 
Among 397 participants who had not initiated ART at baseline, the cumulative 
incidence of ART initiation in the natural course scenario (unweighted study population) 
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was 24% (95% CI: 20%, 29%) at 6 months and 35% (95% CI: 30%, 40%) at 12 months 
(Table 5.3, Figure 5.1). In the never-depressed scenario (weighted incidence if 
participants never had severe depressive symptoms), the cumulative incidence of ART 
initiation was slightly higher: 27% (95% CI: 20%, 34%) at 6 months and 37% (95% CI: 
30%, 44%) at 12 months. In the always-depressed scenario (weighted risk of outcome if 
participants always had severe depressive symptoms), the cumulative incidence of ART 
initiation was somewhat lower:  20% (95% CI: 13%, 27%) at 6 months and 30% (95% 
CI: 22%, 38%) at 12 months.  
Among 342 participants who were not virally suppressed at baseline (HIV RNA 
≥400 copies/mL), the cumulative incidence of viral suppression in the natural course 
was 20% (95% CI: 14%, 25%) at 6 months and 44% (95% CI: 34%, 54%) at 12 months 
(Table 5.3, Figure 5.1). Estimates of cumulative incidence were similar in both of the 
hypothetical depression scenarios. In the never-depressed scenario, the cumulative 
incidence of viral suppression was 19% (95% CI: 11%, 27%) at 6 months and 46% 
(95% CI: 31%, 62%) at 12 months. In the always-depressed scenario, the cumulative 
incidence of viral suppression was 20% (95% CI: 11%, 28%) at 6 months and 48% 
(95% CI: 29%, 68%) at 12 months.  
Severe depressive symptoms (compared with no severe symptoms) decreased 
the cumulative incidence of ART initiation, with CID values comparing always vs. never 
having severe depressive symptoms of -7.5 (95% CI: -17.2, 2.2) percentage points at 6 
months and -7.1 (95% CI: -17.9, 3.7,) percentage points at 12 months (Figure 5.3). 
There were no appreciable differences in the cumulative incidence of viral suppression 
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at 6 months (CID = 0.3 percentage points, 95% CI: -11.3, 11.9) or 12 months (CID = 2.0 
percentage points, 95% CI: -21.8, 25.8).  
Findings were largely unchanged in analyses where we estimated both outcomes 
in the set of participants who had not experienced either outcome at baseline (Figure 
5.4). 
Discussion 
Using longitudinal data on PWID living with HIV in Vietnam, we found that severe 
depressive symptoms decreased the cumulative incidence of ART initiation, but not viral 
suppression, over one year. We used a rigorous methodological approach that 
addressed the episodic nature of depression, time-varying confounding, substantial 
missing data, and common competing events of death and incarceration. By focusing 
on a population disproportionately impacted by both depression and HIV, we sought to 
better understand depression as a cause of phenomena that could lead to poor health 
outcomes and potential onward transmission. Although an inverse relationship between 
depression and HIV treatment-related outcomes has been established, prior work has 
largely focused on HIV patients who were engaged in clinical care (21,25–31). As the 
majority of our study population was newly diagnosed and/or not receiving ART at the 
start of follow-up, this analysis provides insights into the association between 
depression and HIV treatment-related outcomes outside of well-established clinical 
cohorts.  
We contrasted two extreme conditions intended to capture the largest possible 
difference by depression: the risk of the outcome if participants always had severe 
symptoms vs. the risk of the outcome if participants never had severe symptoms. For 
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the ART initiation outcome, the CID for the always- vs. never-depressed scenarios was 
approximately -7 percentage points at both 6 and 12 months. These effect estimates 
relied on small sample sizes (i.e., the subsets of participants who stayed depressed or 
were never depressed, respectively), resulting in wide confidence intervals; that is, a 
CID ranging from a large decrease in ART initiation (-17 to -18 percentage points) to a 
slight increase in ART incidence (2 to 4 percentage points) is compatible with the data. 
Given that the cumulative incidence of ART initiation in the observed study population 
(natural course) was 24% at 6 months and 35% at 12 months, the 7-percentage-point 
decrease in cumulative incidence represented by the point estimate is substantively 
meaningful. Despite this relationship between depression and ART initiation, we did not 
observe an effect of depression on viral suppression: the CIDs at 6 and 12 months were 
both near-zero with extremely wide confidence intervals.   
Our seemingly disparate findings for the ART initiation and viral suppression 
outcomes should be interpreted in light of potential measurement error. We observed 
discrepancies between measurements of ART use and viral load across all study visits. 
Higher-than-expected numbers of participants did not report ART use but had very low 
or undetectable viral load (e.g., 14% of the study population did not report any ART use 
at study baseline, but had viral loads <400 copies/mL). As a result, the estimated 
incidence of viral suppression exceeded that of ART initiation at 12 months, even when 
assessment of both outcomes was restricted to the same set of participants with neither 
ART use nor viral suppression at baseline. Similar discrepancies between reported ART 
use and viral load measurements have been observed in previous research and have 
been considered to result from a combination of elite suppressors and ART reporting 
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bias (140–142). Given that elite suppression is rare (143), we assume that 
discrepancies between ART use and viral load in our study more commonly resulted 
from ART reporting bias. Of particular relevance, in a similar population of PWID living 
with HIV in Vietnam (enrolled in HIV Prevention Trials Network [HPTN] 074), 13% of 
participants who reported no prior ART had antiretroviral drugs detected through study 
screening (142). Although no antiretroviral screening could be performed in our study, 
we used the physician-reported ART variable (in addition to participant reports) to 
reduce possible reporting bias. However, the reporting physician only saw participants 
as part of the study and may have been unaware of ART use overseen by external 
providers if not disclosed by the participant. 
In addition to the possibility of elite suppressors and under-reported ART use, 
apparent discrepancies in our study findings may also result from uncertainty in the viral 
suppression outcome. There was substantial missing data on viral load due to 
insufficient volume of many collected samples. Because missingness was thought to 
occur at random and did not appear to be linked to depression or other participant 
characteristics, we used multiple imputation to impute viral suppression outcomes for 
the 31% and 59% of participants with missing data at 6 and 12 months, respectively. 
There was considerable variability across imputations, resulting in imprecise estimates 
of cumulative viral suppression incidence and corresponding risk differences. Compared 
to cumulative incidence estimates for the ART initiation outcome across imputed 
datasets (Figure 5.5), estimates for the viral suppression outcome showed greater 
variability, particularly at 12 months (Figure 5.6), with this source of uncertainty resulting 
in the wider CID confidence intervals for this outcome vs. the ART outcome (Figure 5.8 
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vs. 5.7). As such, while there may be biological or behavioral mechanisms through 
which depression decreases ART initiation but not viral suppression, we cannot rule out 
missing data and measurement error as factors contributing to this apparently 
paradoxical finding in our study. 
Other study limitations were possible violations of the assumptions (107,109) 
required for valid interpretation of our CIDs as representing causal effects. First of these 
assumptions is sequential conditional exchangeability, which in our case holds that 
participants who never have depression and who always have depression are 
exchangeable, conditional on measured confounders. We controlled for a variety of 
confounders through the use of inverse probability weights, but it is possible that 
unmeasured confounders led to imbalances in depression groups, thereby biasing 
estimates of the effect of depression on our outcomes. The second assumption is 
positivity, which requires that there were participants who were never depressed and 
who were always depressed in all confounder-defined subsets of the study population. 
We used model diagnostics to verify this assumption. Finally, the assumption of 
consistency, or treatment version irrelevance, holds that any variability in treatment (i.e., 
multiple versions of treatment) is irrelevant to the effect of treatment on the outcome. 
Here, we did not model a specific treatment or intervention on depression, and our 
results should only be interpreted as the hypothetical effect of eliminating severe 
depressive symptoms, without specifying the precise treatment or intervention used for 
elimination. Further research on the high burden of depression in PWID and the 
potentially overlapping experiences of stigma and other mental illness in this population 
could inform the design of future intervention.  
 
 65 
Our findings are specific to this study sample, which may not be representative of 
all PWID living with HIV. Although snowball sampling enabled the study team to access 
a hard-to-reach population, the non-random nature of our study sample potentially limits 
generalizability of findings to PWID with HIV in Vietnam who were not recruited. In 
addition, while men who inject drugs are a key population in the Vietnamese HIV 
epidemic in Vietnam, our findings may not be applicable to women who inject drugs, a 
key population for HIV prevention efforts in other parts of the world (144).  
In conclusion, we found that severe depressive symptoms may have hindered 
ART initiation but not viral suppression among PWID living with HIV in Vietnam. During 
the study period (2009-2013), there were extremely limited treatment services for 
depression in Vietnam, but in recent years, mental health services have received 
growing prioritization and funding (88,132). Screening and treating depressive 
symptoms among PWID present opportunities not only to improve mental health and 
drug abuse outcomes, but also to increase uptake of lifesaving HIV treatment. Future 
work probing the seemingly antagonistic effect of depression on treatment uptake – but 
not viral suppression – may help to elucidate the relationships between these two 
outcomes and inform the design of interventions promoting HIV care engagement, 
treatment initiation, and viral suppression among PWID.   
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Table 5.1. Time-fixed and time-varying characteristics of 455 HIV-positive male PWID in Thai Nguyen, Vietnam at 





Median (IQR) or N (%) 
  
Age in years (range 19-60) 35 (30, 39)   
Married or cohabitating 215 (47)   
Full-time employment  315 (69)   
Number of days (in past 90 days) injected heroin 70 (15, 90)   
Any sharing of injection equipment (past 90 days) 332 (73)   
Any sex without a condom (past 90 days) 108 (24)   
Self-rated health as poor 136 (30)   
History of overdose 84 (18)   
Any alcohol use 307 (67)   




Median (IQR) or N (%) 
6 Months 
Median (IQR) or N (%)i 
12 Months 
Median (IQR) or N (%)ii 
Severe depressive symptoms (CES-D≥23)iii 201 (44) 169 (37) 116 (25) 
ART useiv 58 (13) 148 (33) 165 (36) 
CD4 cell count (cells/µl)v 241 (126, 370) 251 (154, 387) 260 (151, 382) 
HIV viral load (log10 copies/mL)vi 4.3 (2.6, 4.9) 3.6 (1.8, 4.5) 3.9 (3.2, 4.5) 
 
i Percentages are based on the total sample size of 455 participants. By 6 months, 55 (12%) participants had experienced competing 
events of death or incarceration.  
ii Percentages are based on the total sample size of 455 participants. By 12 months, 101 (22%) participants had experienced 
competing events of death or incarceration. 
iii There was missing data on CES-D scores (not due to death or incarceration) for 1 participant at baseline, 23 participants at 6 
months, and 27 participants at 12 months. 
iv There was missing data on ART use (not due to death or incarceration) for 6 participants at baseline, 23 participants at 6 months, 
and 27 participants at 12 months. 
v There was missing data on CD4 cell count (not due to death or incarceration) for 9 participants at baseline, 43 participants at 6 
months, and 50 participants at 12 months. 
vi HIV viral load was fully observed at baseline, but missing data (not due to death or incarceration) occurred for 162 participants at 6 






Table 5.2. Distribution of depression, competing events, and missing data over 12 months, by baseline 
depression. 
 
 Severe depressive symptoms, N = 201 
n (%)i 
No severe symptoms, N = 253 
n (%)i 
Severe depressive symptoms   
At 6 months 103 (51%) 65 (26%) 
At 12 months 73 (36%) 43 (17%) 
Incarceration   
At 6 months 9 (4%) 5 (2%) 
At 12 months 18 (9%) 11 (4%) 
Death   
During 0-6 months 30 (15%) 11 (4%) 
During 6-12 months 14 (7%) 16 (6%) 
Missing dataii on ART   
At 6 months  5 (2%) 18 (7%) 
At 12 months 11 (5%) 16 (6%) 
Missing dataii on viral load   
At 6 months 70 (35%) 91 (36%) 
At 12 months 119 (59%) 176 (70%) 
 
i Percentages are based on the sample sizes of 201 participants with severe depressive symptoms at baseline and 253 participants 
with no or mild depressive symptoms at baseline. One participant had a missing CES-D score at baseline. 





Table 5.3. Estimates of 6-month and 12-month cumulative incidence of ART initiation and viral suppression by 
depression scenario and cumulative incidence differences contrasting always-depressed vs. never-depressed 
scenarios. Cumulative incidence estimates for the natural course (observed study population) are provided for reference. 
The study sample for the ART initiation outcome was n=397 participants without ART use at baseline, and the study 
















Always Depressed 0.20 (0.13, 0.27) -0.08 (-0.17, 0.02) 0.30 (0.22, 0.38) -0.07 (-0.18, 0.04) 
Natural Course 0.24 (0.20, 0.29)  0.35 (0.30, 0.40)  
Never Depressed 0.27 (0.20, 0.34)  0.37 (0.30, 0.44)  
Viral Suppression 
Always Depressed 0.20 (0.11, 0.28) 0.00 (-0.11, 0.12) 0.48 (0.29, 0.68) 0.02 (-0.22, 0.26) 
Natural Course 0.20 (0.14, 0.25)  0.44 (0.34, 0.54)  







Figure 5.1. Estimates of 6-month and 12-month cumulative incidence of ART 
initiation and viral suppression. The study sample for the ART initiation outcome was 
n=397 participants without ART use at baseline, and the study sample for the viral 








Figure 5.2. Weighted cumulative incidence of competing events (death, 




Figure 5.3. Estimates of 6-month and 12-month cumulative incidence differences 
for ART initiation and viral suppression, contrasting always-depressed vs. never-
depressed scenario. The study sample for the ART initiation outcome was n=397 
participants without ART use at baseline, and the study sample for the viral suppression 







Figure 5.4. Weighted cumulative incidence of ART initiation and viral suppression 
in the same sample of participants with neither ART initiation nor viral 




















Figure 5.7. Cumulative incidence differences for ART initiation, by imputation, 











Figure 5.8. Cumulative incidence differences for viral suppression, by imputation, 








CHAPTER VI: THE ROLE OF DEPRESSION IN HIV TRANSMISSION AMONG 




Sharing drug preparation and injection equipment is one of the most efficient 
means of HIV acquisition and transmission (4,5), yet coverage of harm reduction 
services for most people who inject drugs (PWID) remains inadequate (2,9,10). For 
PWID living with HIV, barriers to HIV care engagement and antiretroviral therapy (ART) 
use can inhibit viral suppression, resulting in onward HIV transmission to injecting 
partners (8–10). Equipment sharing in the absence of viral suppression continues to 
sustain the HIV epidemic among PWID, particularly in Asia and eastern Europe (11,12). 
Depression could be an underlying cause of HIV transmission among PWID. Up 
to 50% of PWID suffer from severe depressive symptoms (16–20), and depression has 
been linked to both increases in sharing behaviors (36,38–40) and decreases in ART 
initiation and viral suppression (26,28–32). Despite evidence supporting these links, the 
role of depression in HIV transmission among PWID has not been quantified. Prior 
research has focused on individual components of transmission risk (i.e., sharing 
behaviors or viral load) but has not investigated the overall contribution of depression to 
HIV transmission through the combination of these behavioral and biological pathways.  
In this study, we use mathematical modeling to estimate secondary HIV 
transmission events from PWID living with HIV to their potentially susceptible injecting 
partners. We base input parameter values on behavioral and viral load data from PWID 
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living with HIV in Vietnam, where injection drug use drives the HIV epidemic 
(58,59,145). Given continued HIV incidence among PWID (8,11) and the plausible role 
of depression, it is critical to better understand how depression may drive onward 




We modeled parenteral HIV transmissions arising from 455 adult, male PWID 
enrolling in a randomized controlled trial of an HIV prevention intervention in Thai 
Nguyen, Vietnam from 2009 to 2013. Trial details have been published previously (45), 
but briefly, participants were recruited via snowball sampling from the 32 sub-districts of 
Thai Nguyen with the most PWID. The intervention included structural and individual 
components, with randomization occurring at the sub-district level for the former and the 
individual level for the latter. The structural intervention aimed to reduce community-
level HIV and injection drug use stigma, and the individual intervention provided support 
to participants in coping with HIV and reducing both condomless sex and sharing of 
injection drug use equipment. The randomization process resulted in four trial arms: 
individual intervention only, structural intervention only, combined intervention (both 
individual and structural), and control (standard of care). As previously reported (45), no 
differences in injecting or sexual behaviors across intervention arms were observed 






Participants enrolled in the trial responded to a questionnaire in face-to-face 
interviews at baseline and follow-up visits at 6, 12, 18, and 24 months. At each 
interview, participants were asked to name up to ten partners with whom they had 
injected drugs in the prior three months, and for each partner, to report the frequency in 
those three months of: 1) sharing the same needle or syringe, 2) sharing drug solution, 
and 3) sharing the same ampoule of distilled water or novocaine. Participants were also 
asked if each partner had HIV, with possible responses being “Yes”, “No”, or “Don’t 
know”.  
In the parent trial, blood specimens were collected to confirm HIV infection at 
baseline and to measure CD4 cell count at all visits. To obtain viral load data for the 
current analysis, we performed HIV RNA testing on stored plasma specimens using 
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test platform (Roche Diagnostics 
GmbH) with a lower limit of detection of 20 copies/mL. Due to insufficient volume in 
>50% of plasma samples from the 12-, 18-, and 24-month visits, we limited the scope of 
our analysis to data collected at the baseline and six-month follow-up visits.   
The trial questionnaire also assessed depressive symptoms in the past week 
with the Center for Epidemiologic Studies Depression Scale (CES-D), which has been 
validated in Vietnam (50). Consistent with past work in this population (20,46,50,51), we 
defined severe depressive symptoms as CES-D scores ≥23, mild depressive symptoms 






We developed a modified Bernoulli process mathematical model (99,115–118) to 
estimate the expected number of secondary HIV transmission events from each study 
participant in two periods: the three months before baseline and the three months 
before the six-month visit. Transmission estimates were based on viral load 
measurements taken at the end of a given period, reported numbers of injecting 
partners in the period, sharing acts within those partnerships over the specified period, 
and reported partner HIV status. With this model (Equation 1), we estimated the 
probability !"# that study participant $ would transmit HIV to named partner % in a 
specified period, given the probability &# that the partner was already HIV-infected at the 
start of that period, the probability '" of HIV transmission in one sharing act with a 
susceptible partner, and the number of acts ("# between participant and partner over the 
period.   
!"# = *1 − &#-[1 − (1 − '")123]   Equation 1 
We specified the per-act transmission probability '" as a function of viral load 5" 
measured at the end of a given period, an average viral load set-point 56 estimated 
previously (119), and the transmission probability '6 corresponding to that set-point 
(Equation 2). In this expression, '" increases relative to '6 at a rate 7 per log10-unit 




)'6    Equation 2 
We then estimated >", the total modeled number of secondary transmissions for 
each participant $ across all partners % in a given three-month period (Equation 3).  
>" = ∑#	!"#     Equation 3 
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Finally, we summed the >" values for each of the two time periods (the three 
months prior to baseline and the three months prior to the six-month follow-up visit) for a 
total number of estimated transmissions across participants in those two windows. 
Model Parameters 
The number of sharing acts (("#) and the probability (&#) of partner HIV infection 
at the start of a given period were based on questionnaire reports at baseline and six 
months, with &# taking a value of 0 if the partner was reportedly HIV-negative and 1 if a 
partner was reportedly already HIV-positive. For partners whose HIV status was 
reported as unknown, we specified &# based on the estimated overall HIV prevalence 
(34%) among PWID in Thai Nguyen during the study period (57–59). Participant viral 
load (5A) was fully observed at trial baseline, and for missing viral load due to insufficient 
samples at six months (31% of participants), we used multiple imputation by chained 
equations (113,114) to impute viral suppression status and assign viral load in 50 
imputed datasets. We used published estimates in the scientific literature (119–121) for 
the average viral load set-point (56 = log10 4.5 copies/ml), transmission probability per 
sharing act at that set-point ('6= 0.008), and increases or decreases in infectiousness 
per log10 change in viral load relative to the set-point value (7 = 2.09).  
Prior modeling work (93–98) has relied on a single per-act probability value that 
was estimated without specification of (or differentiation by) type of sharing act (120). 
Given that this transmission probability may be similar across sharing acts (146), we 
conducted one set of model analyses in which we included all types of sharing acts 
(needles or syringes, drug solutions, and ampoules of distilled water or novocaine) as 
potential transmission events, using the single value of '6 for all types. Due to 
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uncertainty about the extent to which the standard probability estimate reflects all acts 
vs. needle- or syringe-sharing specifically, we also conducted a set of analyses in which 
we included only needle- or syringe-sharing acts in the model to estimate a lower bound 
on modeled transmissions.   
Modeling Analysis 
To incorporate uncertainty around model inputs into our model outputs, we ran 
the model 50 times for each of 50 imputed datasets (2,500 model runs total). In each 
model run, we drew values for &# (for partners with unknown HIV status), 7, and '6 from 
the distributions specified by their published summary estimates and confidence limits. 
Participants were excluded from the analysis at six months if they experienced a 
competing event between baseline and six months (12% died or incarcerated) or 
missed the 6-month visit not due to a competing event (5%). 
To evaluate differences in predicted transmission events by depression, we 
stratified the population according to baseline depressive symptoms (severe, mild, or no 
symptoms) and compared the total number of estimated transmissions by depressive 
symptom group, the probability of infection per partner, and the number of estimated 
transmissions per participant. To account for different sample sizes by depression, we 
weighted the number of total transmissions such that each group was upweighted to 
stand in for the full study population (e.g., transmissions for 202 participants with severe 
symptoms were multiplied by 2.25 [total sample size N=455 divided by depression 
group n=202]). Since depressive symptoms were assessed at both baseline and six 
months, we conducted a secondary analysis of 6-month transmission by 6-month 
depressive symptoms (instead of baseline depressive symptoms).  
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To account for possible misreporting of partner HIV status, we performed a 
sensitivity analysis in which a random sample of 25% of partner HIV status reports of 
“Positive” or “Negative” in each model run were assumed to be inaccurate (i.e., status 
was reversed for 25% of partners reported to be HIV-positive or HIV-negative). We also 
performed a sensitivity analysis around the assumed relationship between viral load and 
the transmission probability, as the current estimate for 7 is based on sexual 
transmission and may not strictly hold in the context of injection drug use. For this 
analysis, we used a constant transmission probability instead of deriving the probability 
from viral load measurements (120). 
In addition to the transmission model, we performed descriptive analyses on viral 
load and behavioral data for the overall study population and by baseline depressive 
symptoms. These analyses included a summary of partner HIV susceptibility, in which 
we defined “susceptible” partners on the basis of participant reports that the partner 
was: a) HIV-negative or of unknown HIV status, and b) participating in ≥1 sharing act. 
For “most susceptible” partners, the participant was also observed to have 
unsuppressed viral load. Analyses were conducted using R Version 3.4.3 (105).  
Ethics 
The parent trial and this study were approved by the ethical review committees at 
the Thai Nguyen Center for Preventive Medicine, the Johns Hopkins Bloomberg School 
of Public Health, and the University of North Carolina at Chapel Hill Gillings School of 






Among the 455 participants at baseline, the median age was 35 years, almost 
half (47%) were married or cohabitating, and most (69%) were employed full-time. Most 
participants (73%) reported sharing injection drug use equipment with partners over the 
prior three months. Three-quarters (74%) of participants reported no HIV diagnosis 
before HIV testing at enrollment, and 41% had CD4 cell count less than 200 cells/µL.  
Descriptive Analyses 
At baseline, participants had a median viral load of 4.3 log10 copies/mL and 
reported a total of 833 injecting partners (average of 1.8 per participant) in the prior 
three months; most partners were reported to have unknown HIV status (45%) or to be 
HIV-negative (30%) (Table 6.1). On average, participants reported 15.5 sharing acts per 
partner during the prior three months (primarily sharing ampoules or solutions, rather 
than needles/syringes). At the six-month visit (i.e., after HIV diagnosis and risk reduction 
counseling), median viral load decreased to 3.6 log10 copies/mL, and the total number of 
injecting partners over the prior three months dropped an average of 0.7 per participant. 
Participants reported fewer partners (44%) who were potentially susceptible to HIV (i.e., 
negative or unknown HIV status) and fewer sharing behaviors (mean 4.3 acts per 
partner during the prior three months).  
At both baseline and six months, there were few clear differences in viral load or 
sharing behaviors according to baseline depressive symptoms. Participants with severe 
depressive symptoms had both slightly higher viral load and fewer partners who were 
potentially susceptible to HIV (compared to mild or no symptoms), whereas participants 
with mild depressive symptoms reported somewhat higher numbers of sharing acts per 
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partner (compared to severe or no symptoms). However, estimates were imprecise and 
confidence intervals overlapped heavily.  
At baseline, 333 of 833 partners (40%) were considered to be most susceptible 
to HIV (Figure 6.1). This portion decreased to only 20 of 251 partners (8%) at six 
months. When stratified by index participants’ baseline depressive symptoms, these 
most susceptible partners were more likely to be reported by participants with severe 
symptoms at baseline, but by participants with mild symptoms at six months.  
Modeling Analyses 
Across 2,500 model runs, we estimated a median of 41.2 (2.5th, 97.5th 
percentiles: 33.2, 49.2) secondary transmissions from all reported sharing acts with 833 
injecting partners in the three months prior to the baseline visit. This estimate fell to 3.0 
(2.2, 3.8) transmissions when only needle- or syringe-sharing acts were modeled. For 
251 partners reported at six months, we estimated a median of 1.2 (0.8, 1.7) 
transmissions in the prior three months based on all sharing acts and 0.1 (0.0, 0.2) 
based only on needle- or syringe-sharing.  
The highest numbers of secondary transmissions were predicted for participants 
with severe depressive symptoms across time periods and types of sharing acts 
modeled (Figures 6.2, 6.3). In the three months prior to baseline, 45.7 (36.7, 54.7) 
transmissions from all reported sharing acts were predicted to arise from the study 
population had all 455 participants experienced severe depressive symptoms; this 
decreased to 39.6 (31.0, 49.8) transmissions if all participants experienced mild 
symptoms and 35.9 (28.8, 42.8) transmissions if all participants experienced no 
symptoms. When modeled transmissions were restricted to needle- or syringe-sharing 
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acts, these estimates decreased to 4.9 (3.3, 6.7) transmissions for severe symptoms, 
2.0 (1.4, 2.9) transmissions for mild symptoms, and 1.0 (0.8, 1.2) transmissions for no 
symptoms.  
In follow-up months 3-6, secondary transmissions modeled for all sharing acts 
fell to 1.9 (1.1, 2.8) had all participants experienced severe symptoms, 1.3 (0.8, 2.1) for 
mild symptoms, and 0.2 (0.1, 0.5) for no symptoms. Estimates further decreased when 
only needle- or syringe-sharing acts were modeled; non-zero transmissions were 
predicted only for participants with severe symptoms. These results were consistent 
regardless of whether the baseline or 6-month depressive symptom measure was used 
(Figure 6.4).  
When we accounted for possible misreporting of partner HIV status, there was 
greater uncertainty in transmission estimates but differences by depression were similar 
(Figures 6.5, 6.6, 6.7). When we assumed a constant transmission probability 
regardless of viral load, greater transmissions at baseline were predicted for participants 
with mild symptoms vs. those with severe symptoms, possibly reflecting participants 
with mild symptoms who reported sharing behaviors with susceptible partners but had 
low or suppressed viremia at that time (Figures 6.8, 6.9, 6.10). 
The majority of modeled transmissions arose from a small number of 
participants. Given that most participants had zero predicted transmissions, the mean 
probability of infection per partner and the mean transmission events per participant 
were heavily weighted towards zero regardless of depressive symptoms. When 
modeling transmission using all sharing acts reported at baseline, the mean probability 
of infection per partner was 0.05 for each depressive symptom group. This mean 
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probability fell to near-zero when only needle- or syringe-sharing acts were modeled at 
baseline and regardless of type of sharing act at six months. However, there were 
notable outliers with higher mean probability values per partner, particularly for partners 
of participants with severe depressive symptoms (Figure 6.11). The mean transmissions 
per participant ranged from 0 to 3 across time points, types of sharing acts, and 
depressive symptoms. The small number of participants with non-zero predicted 
transmission events disproportionately had severe depressive symptoms (Figure 6.12). 
Discussion 
In this study of PWID living with HIV in Vietnam, we used mathematical modeling 
to estimate secondary HIV transmission events from PWID to their potentially 
susceptible injecting partners. A high number of secondary transmissions was predicted 
for the three months prior to study baseline when transmission was modeled for all 
reported sharing behaviors (sharing ampoules, solutions, and needles/syringes); this 
estimate dramatically decreased when only needle- or syringe-sharing behaviors were 
modeled. These disparate findings demonstrate the sensitivity of model estimates to the 
assumed infectivity of different sharing behaviors, a phenomenon that has not been 
routinely considered in prior modeling studies of injection-related HIV transmission. Due 
to substantial declines across all reported sharing behaviors after baseline, we 
estimated that very little secondary transmission occurred during follow-up months 3-6.  
Prior research has linked depression to increased sharing behaviors (36,38–40) 
and decreased ART initiation and viral suppression (26,28–32), and in the current 
analysis, we found some evidence of greater secondary transmissions for PWID with 
depression. Across analyses, the highest numbers of total secondary transmissions 
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were predicted for participants with severe depressive symptoms. However, there was 
substantial variability in the magnitude of differences across model simulations, time 
points assessed, and specific risk behaviors modeled. The majority of modeled 
transmissions arose from only a small number of participants, resulting in group 
averages of the probability of infection per partner and transmission events per 
participant being heavily weighted towards zero regardless of depressive symptoms. 
Given the multi-faceted nature of transmission, it is plausible that depression has a 
combination of synergistic and antagonistic effects, the net sum of which are the small 
increases in projected transmission observed in this modeling analysis. 
We expect that our model predictions underestimate all true transmissions 
arising from this population during the study period. Our model relied on self-reported 
sharing behaviors, and social desirability bias may have led to underestimates of these 
sensitive behaviors. Due to the time horizon specified in the questionnaire, our model 
predictions do not capture the first three months following baseline. In addition, missing 
data precluded transmission estimates for participants who experienced a competing 
event between baseline and six months or who missed the 6-month visit for other 
reasons. Further, we focused on transmission to injecting partners, excluding sexual 
transmission. However, condomless sex was reported infrequently among participants, 
so the exclusion of sexual transmission is not expected to have had a substantial impact 
on transmission estimates. We additionally note that our model assumes that viral load 
measures taken at baseline and six months applied to the prior three months, which 
might have been especially likely to underestimate transmission in the second interval, 
when viral loads were more likely to have been decreasing over time due to diagnosis 
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and treatment. Finally, we note that our model only predicts secondary transmissions 
over a very limited period of time, and does not estimate transmission events arising 
from partners of participants.  
Despite underestimating transmission, our modeling projections suggest a 
disproportionate burden of severe depressive symptoms among those few participants 
from whom transmissions were predicted to arise. To investigate the extent to which 
successful depression treatment could avert future infections, future modeling work 
could simulate potential intervention scenarios to decrease depressive symptoms and 
subsequently lower sharing behaviors and viral load (as informed by this study). Models 
could vary the coverage and efficacy of interventions to more realistically reflect 
depression screening and treatment approaches that could be implemented among 
PWID. Depression treatment could be modeled alongside other current prevention 
interventions (ART, needle exchanges, methadone maintenance) to understand the 
optimal combination of these approaches in decreasing HIV incidence among PWID. 
More generally, future models of injection-related HIV transmission should examine 
uncertainties in the infectivity of different sharing behaviors and the relationship 
between viral load and transmission probability in the context of injection drug use. 
These assumptions substantially influenced this study’s transmission estimates and are 
understudied phenomena with important implications for our understanding of HIV 
transmission among PWID.  
While the net contribution of depression to onward transmission did not appear 
substantial, there was a skewed distribution of transmissions by depression status, with 
greater secondary transmissions predicted for participants with severe depressive 
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symptoms. Our findings reflect a complex relationship of depression with HIV 
transmission, and further modeling analyses could investigate the potential impact of 
depression interventions on continued HIV incidence among PWID. Depression 
interventions may further decrease the small number of participants with estimated 
secondary transmissions, in addition to providing widespread mental health benefits for 









N = 455 
Baseline depressive symptoms 
Severe 
n = 202 
Mild 
n = 115 
None 
n = 138 
Baseline characteristics 
Median (IQR) participant viral load  4.3 (2.6, 4.9) 4.5 (3.1, 5.0) 4.1 (1.9, 4.7) 4.4 (2.2, 4.9) 
Number of injecting partners (last 3 months) 833 400 211 222 
Partner HIV status (% of partners)     
Reported to be HIV-negative 30% 29% 26% 36% 
Reported to be unknown 45% 43% 49% 47% 
Mean (range) acts per partner (last 3 months) 
Sharing ampoules 5.5 (0, 90) 5.4 (0, 90) 5.8 (0, 90) 5.6 (0, 90) 
Sharing solutions 9.1 (0, 90) 9.1 (0, 90) 9.3 (0, 90) 8.9 (0, 90) 
Sharing needles or syringes 0.9 (0, 30) 1.1(0, 30) 1.2 (0, 30) 0.4 (0, 30) 
6-month characteristics 
Number (%) for follow-up 
Attended visit 377 (83%) 158 (78%) 97 (84%) 122 (88%) 
Missed visit: competing event 55 (12%) 39 (19%) 8 (7%) 8 (6%) 
Missed visit: no competing event 23 (5%) 5 (2%) 10 (9%) 8 (6%) 
Median (IQR) participant viral load*  3.6 (1.8, 4.5) 3.8 (2.0, 4.6) 3.4 (1.8, 4.3) 3.7 (1.6, 4.5) 
Number of injecting partners (last 3 months) 251 117 69 65 
Partner HIV status (% of partners)     
Reported to be HIV-negative 24% 31% 17% 17% 
Reported to be unknown 20% 15% 20% 31% 
Mean (range) acts per partner (last 3 months) 
Sharing ampoules 1.4 (0, 30) 1.3 (0, 30) 1.5 (0, 30) 1.5 (0, 30) 
Sharing solutions 2.5 (0, 30) 2.1 (0, 30) 4.8 (0, 30) 0.7 (0, 30) 
Sharing needles or syringes 0.4 (0, 12) 0.6 (0, 7.5) 0.2 (0, 7.5) 0.3 (0, 12) 
* Among 377 participants who attended the 6-month visit, 139 had missing data on viral load due to 





Figure 6.1. Distribution of potentially susceptible partners overall and by baseline 
depressive symptoms. Percentages are based on the 833 partners reported by 455 








Figure 6.2. Modeled secondary transmission events in the three months prior to 
baseline by depressive symptom group. Each group is upweighted to represent the 
full study population at baseline (n = 455). Estimates from 2,500 model runs are plotted 






Figure 6.3. Modeled secondary transmission events in follow-up months 3-6 by 
depressive symptom group. Each group is upweighted to represent the full study 
population at the six-month follow-up visit (n = 377). Estimates from 2,500 model runs 






Figure 6.4. Modeled secondary transmission events in follow-up months 3-6 by 
depressive symptoms assessed at 6 months (instead of baseline). Each group is 
upweighted to represent the full study population at the six-month follow-up visit (n = 
377). Estimates from 2,500 model runs are plotted by type of sharing act (all sharing 







Figure 6.5. Sensitivity analysis accounting for possible misreporting of partner 






Figure 6.6. Sensitivity analysis accounting for possible misreporting of partner 






Figure 6.7. Sensitivity analysis accounting for possible misreporting of partner 






Figure 6.8. Sensitivity analysis allowing for constant transmission probability 






Figure 6.9. Sensitivity analysis allowing for constant transmission probability (6-






Figure 6.10. Sensitivity analysis allowing for constant transmission probability (6-






Figure 6.11. Mean probability of infection (with ranges) for injecting partners 
reported at baseline and 6 months by depressive symptoms. Means and ranges 
are based on 2,500 model runs and are reported separately by the types of sharing acts 






Figure 6.12. Mean numbers of secondary transmission events (with ranges) per 
participant at baseline and 6 months by depressive symptoms. Means and ranges 
are based on 2,500 model runs and are reported separately by the types of sharing acts 








CHAPTER VII: CONCLUSIONS 
 
Summary of Findings 
This dissertation study was motivated by the disproportionately high burden of 
HIV and depression among PWID. We sought to better understand the role of 
depression in perpetuating HIV transmission, hypothesizing that depression increases 
risk behaviors and uncontrolled viremia, ultimately leading to a higher likelihood of 
transmission to injecting and sexual partners of PWID. These possible effects of 
depression were investigated among PWID in Vietnam, a key population in the 
country’s HIV epidemic. Given persistently high HIV incidence among PWID, it is critical 
to better understand how depression may drive onward transmission and the extent to 
which successful depression treatment could avert future infections.  
This study used longitudinal data collected from 455 PWID living with HIV who 
enrolled in a randomized controlled trial of a prevention intervention in Thai Nguyen, 
Vietnam from 2009 to 2013. We combined causal inference methods with mathematical 
modeling to investigate the individual components of transmission risk (i.e., risk 
behaviors and viral load) as well as to estimate the overall contribution of depression to 
HIV transmission through the combination of these behavioral and biological pathways.  
In the study population, the prevalence of severe depressive symptoms was 44% 
at baseline and 33% on average over follow-up visits at 6, 12, 18, and 24 months. In our 
Aim 1 analysis of depression and transmission risk behaviors, we found that severe 
depressive symptoms increased the risk of sharing injection equipment but not the risk 
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of condomless sex over 24 months of follow-up. We also found mixed results in the Aim 
2 analysis, in which severe depressive symptoms decreased the cumulative incidence 
of ART initiation, but not viral suppression, at 6 and 12 months. Combining behavioral 
and viral load data in the Aim 3 transmission model, we found some evidence of greater 
secondary transmissions for PWID with depression, albeit with substantial variability 
across model simulations. A small number of participants were estimated to drive the 
majority of projected transmission events, but of note, these few participants 
disproportionately had severe depressive symptoms. 
Taken together, our findings suggest that intervening on depression in this PWID 
population could reduce sharing injection equipment and improve ART uptake, but that 
other drivers of condomless sex and low viral suppression should be investigated for 
future intervention. These disparate findings reflect a complex relationship of depression 
with onward HIV transmission. Given the multi-faceted nature of transmission, it is 
plausible that depression has a combination of synergistic and antagonistic effects. We 
found evidence that depression is associated with a higher frequency of injecting 
partners (Aim 3) and sharing acts within those partnerships (Aims 1 and 3), but that 
those partners may be more likely to already have HIV (Aim 3). Similarly, while 
depression leads to lower initiation of ART (Aim 2) and slightly higher viral load (Aim 3), 
overall incidence of viral suppression did not vary by depression (Aim 2), and small 
differences in viral load are unlikely to disproportionately drive transmission. While the 
net contribution of depression to onward transmission did not appear substantial, there 
was a skewed distribution of transmissions by depression status. Depression 
interventions may further decrease the small number of participants with estimated 
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secondary transmissions, in addition to providing widespread mental health benefits for 
this PWID population.  
Strengths and Limitations 
The strengths and limitations of this dissertation are summarized with respect to 
key threats to the internal and external validity of epidemiological analyses. 
Confounding 
The assumption of no unmeasured confounding (i.e., that participants with and 
without depression are exchangeable) is critical to using observational studies for 
causal inference. Depression was prevalent among participants at the study start, and 
there were likely important differences (e.g., HIV disease progression, injection drug use 
and other substance use, other psychiatric comorbidities) between participants with and 
without depression that also affected the outcomes of interest. To reduce bias from 
these preexisting differences, we used a rigorous methodological approach in Aims 1 
and 2 to control for a variety of time-fixed and time-varying confounders. However, we 
did not have measures of all possible confounders and cannot rule out the possibility 
that unmeasured confounding biased estimates of the effects of depression on 
transmission risk behaviors, ART initiation, or viral suppression.  
Measurement 
Key study variables relied on self-reported data which may be inaccurate due to 
social desirability bias (e.g., under-reporting of sharing behaviors, over-reporting of ART 
use or HIV-positive status for susceptible partners) and recall bias (e.g., incomplete 
reporting of numbers of partners and sharing acts). However, participants reported high 
levels of (illegal and stigmatizing) drug use; they had also been recruited into the study 
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by current and former PWID (already aware of the participant’s injection drug use), 
suggesting limited potential for social desirability bias. To aid recall, participants were 
asked about injecting and sexual behaviors from only the past three months, rather than 
the full 6-month interval between study visits.  
Another possible source of measurement error is this study’s use of the CES-D, 
which indicates probable depression but is not a clinical diagnosis. However, the CES-D 
has high reliability and validity when compared with psychiatric assessment, including 
validation among people living with HIV in Vietnam (50). Measurement of depression 
among PWID is challenging, given that depression may be an antecedent or 
consequence of injection drug use (74,76), and the short-term effects of drug use 
reduce negative emotions, such as depressed mood (75). However, the CES-D has 
been used widely in PWID populations, with strong evidence of its ability to detect high 
levels of depressive symptoms despite co-occurring drug use (47–49).  
Missingness 
There was substantial missing data on viral load that resulted from insufficient 
sample volume (<1mL) for stored specimens at follow-up visits: 31% of specimens at 6 
months, 59% at 12 months, 48% at 18 months, and 55% at 24 months. Because 
missingness was thought to occur at random, we used MICE to impute viral 
suppression (Aim 2) and subsequently assign viral load (Aim 3). However, there was 
considerable variability across imputations, resulting in imprecise estimates of viral 
suppression incidence and the potential for bias due to differential missingness by 
unknown factors. To limit the influence of missing data in this study, we evaluated the 
viral suppression outcome in Aim 2 at the two earliest follow-up visits (6 and 12 
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months), and we restricted our focus of the transmission model to only baseline and 6 
months. Outside of viral load data, there was very limited missing data on other key 
study variables. 
Selection 
Our findings are specific to this study sample, which may not be representative of 
all PWID living with HIV in Vietnam. Although snowball sampling enabled the study 
team to access a hard-to-reach population, the non-random nature of our study sample 
potentially limits the applicability of our findings to PWID with HIV in Vietnam who were 
not recruited.  
Generalizability 
Our study focused on an important population in the Vietnamese HIV epidemic, 
and findings may be relevant to other parts of Asia and Eastern Europe, where the HIV 
epidemic is concentrated among similar groups of men who inject drugs. Findings may 
be less relevant to other HIV populations, particularly the large, generalized epidemics 
of sub-Saharan Africa driven by sexual transmission. However, there is increasing 
relevance to the opioid epidemic in the US, as opioid users transition to injection drug 
use and engage in sharing behaviors. In addition, this study demonstrates a 
methodological approach that can be applied to other populations and settings to 
understand individual determinants of HIV transmission and their net contribution to 
ongoing infection.  
Public Health Implications and Future Directions 
Future research probing our mixed findings for the effect of depression on 
sharing injection equipment (but not condomless sex) and on ART initiation (but not viral 
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suppression) will inform the design and implementation of interventions for PWID. To 
shed light on the extent to which successful depression treatment could avert future 
infections, modeling work could simulate potential intervention scenarios that vary the 
coverage and efficacy of depression interventions designed to decrease depressive 
symptoms and subsequently lower sharing behaviors and viral load (as informed by this 
study). Depression treatment could be modeled alongside current interventions (ART, 
needle exchanges, methadone maintenance treatment [MMT]) to understand the 
optimal combination of these approaches in decreasing HIV incidence among PWID.  
Addressing the high burden of depression among PWID through future 
intervention and treatment will improve the mental health of this population in addition to 
possible HIV prevention benefits. Current work in Vietnam is developing and 
implementing evidence-based interventions to facilitate the engagement of PWID in 
both HIV and substance use care (e.g., ClinicalTrials.gov NCT03952520). Incorporation 
of mental health services alongside HIV and substance use care is complementary and 
has the potential to further improve HIV and drug use-related outcomes. Specifically, 
incorporating depression screening and treatment into HIV and substance use care fits 
well with increasing prioritization and funding for depression in Vietnam in recent years. 
To inform possible integration of depression, HIV, and substance use care, 
depression screening and treatment interventions could be piloted at ART or MMT 
clinics, providing an access point to PWID with possible comorbid depression and HIV. 
To reach PWID who are not already engaged in care, qualitative work among ART or 
MMT clients engaged in depression interventions could solicit input on recruitment 
strategies and determine the feasibility of ART or MMT clients as recruiters of PWID 
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outside of clinic settings (given the success of using current and former PWID as 
recruiters in this study’s parent trial). Clinic-based interventions could consist of a brief 
screening tool (such as the CES-D), and for participants who screen positive for 
depressive symptoms, provision of evidence-based depression treatment (e.g., 
antidepressant medication prescribed alongside ART or MMT; cognitive behavioral 
therapy or problem solving therapy at clinic visits).  
In conclusion, this dissertation study found some evidence that interventions to 
treat depression may decrease injection equipment sharing and improve ART uptake, 
lowering the corresponding risk of HIV transmission among PWID. Screening and 
treating depressive symptoms among PWID presents an opportunity not only to benefit 
mental health but also to reduce the harms of drug abuse and improve HIV outcomes in 





Appendix 1. R packages used in analyses.  
Source: CRAN package repository https://cran.r-project.org/ 
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